

## CURRICULUM VITAE

Craig T. Jordan, Ph.D.

**1. Biographical Sketch**

**Current Position:** Professor, Division of Hematology  
 University of Colorado, Anschutz Medical Campus  
 12700 East 19<sup>th</sup> Ave, Room 10016  
 Research Complex 2, Campus Box B170  
 Aurora, CO 80045  
 303-724-8165 (phone)  
 email: craig.jordan@cuanschutz.edu

**2. Education**

<b><u>Year</u></b>	<b><u>Degree/Position</u></b>	<b><u>Institution</u></b>
1984	B.A. Molecular Biology	University of California, Berkeley
1991	Ph.D. Molecular Biology	Princeton University
1991-1992	Postdoctoral Fellow	Whitehead Institute, MIT
1992-1993	Sr. Postdoctoral Fellow	Dept. of Molecular Biology, Genentech Inc.

**3. Academic Appointments**

1997-2003	Asst. Professor of Medicine	Univ of Kentucky Medical Ctr
1997-2003	Asst. Professor of Micro/Immunology	Univ. of Kentucky Medical Ctr
2003	Associate Professor of Medicine	Univ. of Kentucky Medical Ctr
2003-2008	Associate Prof of Medicine	Univ. of Rochester Medical Ctr
2004-2008	Associate Prof of Biomedical Genetics	Univ. of Rochester Medical Ctr
2003-2013	Director, Hematologic Malignancies Translational Research Program	Univ. of Rochester Medical Ctr
2008-2013	Professor of Medicine	Univ. of Rochester Medical Ctr
2008-2013	Prof of Biomedical Genetics	Univ. of Rochester Medical Ctr
2013-2016	Adjunct Professor of Medicine	Univ. of Rochester Medical Ctr
2016-2020	Vice Chair of Basic Research	Dept of Medicine, Univ of Colorado
2013-2024	Chief, Division of Hematology	University of Colorado, Anschutz
2013-present	Professor of Medicine with Tenure	University of Colorado, Anschutz
2013-present	Nancy Carroll Allen Professor	University of Colorado, Anschutz

**4. Other Professional Positions**

1993-1994	Sr Scientist, Head of Bone Marrow Gene Therapy Program	Aastrom Biosciences Inc. Ann Arbor, MI.
1994-1997	Section Manager, Stem Cell Biology and Gene Therapy Group	Somatix Therapy Corporation Alameda, CA
1994-1997	Director, Flow Cytometry Laboratory	Somatix Therapy Corporation Alameda, CA
1997	NIAID consultant	National Institutes of Health

1998-2002	Scientific Advisory Board	Bethesda, MD Cytomatrix, Inc. Woburn, MA
1999-2003	Consultant	Deltagen, Inc. Palo Alto, CA.
2005-present	Co-Founder	LeuChemix Inc. Woodside, CA
2014-2021	Co-leader Hematologic Malignancies program	Univ of Colorado Cancer Center

## **5. Honors, special recognitions and awards**

1989	New Jersey Cancer Commission Predoctoral Fellowship
1991	Helen Hay Whitney Postdoctoral Fellowship
1999	Leukemia and Lymphoma Society (Kentucky Chapter) – Chad Kopple Award
2003-2008	Leukemia and Lymphoma Society Scholar Award
2008	Leukemia and Lymphoma Society Stohlman Scholar
2011	Philip and Marilyn Wehrheim Chair in Cancer Research
2013	Nancy Carroll Allen Chair in Hematology
2024	H index = 81

## **6. Membership in Professional Organizations**

1998-present	International Society of Experimental Hematology (ISEH)
2002-2004	International Society of Experimental Hematology (ISEH) Chairperson, Publications Committee
2002-2004	International Society of Experimental Hematology (ISEH) Member, Board of Trustees
1999-2002	American Society of Gene Therapy
2000-2004	American Association for the Advancement of Science
1998-present	American Society of Hematology
2003-2005	American Society of Hematology, Scientific Committee on Stem Cells
2006-2008	American Society of Hematology, Chair - Scientific Committee on Stem Cells
2002-present	American Association for Cancer Research
2007-present	International Society for Stem Cell Research
2010-2014	International Society of Experimental Hematology (ISEH) Publications Committee

## **7. Major Committee and Service Responsibilities**

1998	Steering Committee - College of Medicine Research Challenge Initiative.
1998-99	Search Committee - Faculty recruitment in Molecular Genetics, UKMC
1998-99	UK Medical Center - Gene Therapy Task Force.
1999-02	American Cancer Society Institutional Research Grant Review Committee.
1999-02	University of Kentucky Institutional Biosafety Committee.
1999-00	Steering Committee – UK Initiative on Genetics
2000	Co-organizer – “Clinical Infection Control in Gene Therapy: A Multidisciplinary Conference” (National conference hosted by UK, 10/99).
2000-05	University of Kentucky Committee on Intellectual Properties
2001-02	Search Committee – Hematology/Oncology Division Chief

2001	Co-organizer – “Symposium on Genomics and Bioinformatics” (regional conference hosted by the Univ. of Kentucky).
2001-2002	University of Kentucky - Physician Scientist Award Committee
2001-2002	Search Committee – DNA repair faculty position
2002	Member - President’s task force on institutional conflict of interest
2002-2003	Search Committee-Bioinformatics faculty position (UK)
2003	Co-organizer – University of Rochester Experimental Hematology Program
2003-2012	Cancer Center Executive Committee (URMC)
2004	Co-organizer – “Malignant stem cells in leukemia and solid tumors” National conference, sponsored by the Leukemia and Lymphoma Society
2012	Promotions Committee, Dept of Medicine (URMC)
2014-2017	Dean’s Advisory Committee, University of Colorado Denver
2014-present	Co-Leader, Hematologic Malignancies Program, Univ of Colorado Cancer Ctr
2014-present	Member, Molecular Biology Graduate Program, University of Colorado Denver
2014-present	Member, Cancer Biology Graduate Program, University of Colorado Denver
2015-present	Member, Biomedical Sciences Program, University of Colorado Denver
2017-present	Member, Dean’s Research Advisory Committee, University of Colorado Denver
2017-2019	Member, Strategic Infrastructure for Research Com, Univ of Colorado Denver

## **8. Licensure and Board Certification**

Not applicable

## **9. Inventions, intellectual property and patents**

### **Issued U.S. Patents**

Title: Methods to Impair Hematologic Cancer Progenitor Cells and Compounds Related Thereto  
Number: 6,733,743

Title: Use of parthenolide derivatives as antileukemic and cytotoxic agents  
Number: 7,312,242

Title: Melampomagnolide B derivatives as antileukemic and cytotoxic agents  
Number: 8,884,027

## **10. Review and referee work**

### **Editorial:**

1999-2004	Editorial Board member	<i>Leukemia</i>
2000-2004	Editorial Board member	<i>Current Gene Therapy</i>
2001-2003	Editorial Board member	<i>Experimental Hematology</i>
2003	Acting Associate Editor	<i>Haematologica</i>
2004-2005	Editorial Board member	<i>Stem Cells</i>
2008-2012	Academic Editor	<i>PLoS Biology</i>
2012-2017	Editorial Board member	<i>Molecular Cancer Therapeutics</i>
2016-2019	Editorial Board member	<i>Blood</i>

2014-present	Editorial Board member	<i>Cell Stem Cell</i>
<b><u>Grant Review:</u></b>		
1997	NIH/NCI P01 site visit Ad hoc reviewer	University of Michigan Ann Arbor, MI
1997	NIH/SBIR study section Ad Hoc reviewer	National Institutes of Health Bethesda, MD
1997	NIH/NCI P01 site visit Ad hoc reviewer	Johns Hopkins University Baltimore, MD
1998	American Heart Association Study Section, Ad Hoc Reviewer	Hartford, Conn.
1998	NIH/SBIR study section Ad Hoc reviewer	National Institutes of Health Bethesda, MD
1998	NIH/NIMH SBIR study section Ad Hoc reviewer	National Institutes of Health Bethesda, MD
1998	NIH/SBIR study section, Hem-2 Ad Hoc reviewer	National Institutes of Health Bethesda, MD
2000-2001	National Cancer Institute of Canada Member – Study section, Panel H	Toronto, Ontario Canada
2001	NIH/SBIR study section, Hem-2 Ad hoc reviewer	National Institutes of Health Bethesda, MD
2001-2004	American Cancer Society Member - LIB Study Section	Atlanta, Georgia
2001	Italian Telethon Foundation Grant Program External reviewer	
2001	NIH/NIA RFA on stem cells in aging Member, R01 special study section	National Institutes of Health Bethesda, MD
2001-2002	Veterans Administration Merit Award Ad hoc reviewer	Lexington, KY
2002	NIH/NIDDK, P01 reviewer “Stem cells and signal transduction”	National Institutes of Health Bethesda, MD
2002	NIH, HEM-1 study section Ad Hoc reviewer	National Institutes of Health Bethesda, MD
2002	NIH/NIDDK RFA on stem cell genomics Member, U01 special study section	National Institutes of Health Bethesda, MD
2003	Science Foundation Ireland External reviewer	
2003-2005	American Society of Hematology (ASH) Member, Scholar Award Study Section	Washington, DC
2003	Kentucky Lung Cancer Research Program External reviewer	
2003-2004	Genome Canada External reviewer	
2004	Leukemia Research Fund of Canada Ad hoc reviewer	Toronto, Ontario Canada
2004	Leukemia Research Fund (United Kingdom) External reviewer	
2004	Dutch Cancer Society, external reviewer	
2004-2005	NIH, Hematopoiesis (HP) study section	National Institutes of Health

2004-2005	Ad hoc reviewer American Cancer Society Co-Chair, LIB Study Section	Bethesda, MD Atlanta, Georgia
2005-2007	American Cancer Society Chair, LIB Study Section	Atlanta, Georgia
2006	Kentucky Lung Cancer Research Program External reviewer	
2006-2009	Molecular oncology (MONC) study section	National Institutes of Health
2006-2009	Dept of Defense, PBY-3/4 breast cancer panel	Washington, DC
2008	Chair, NCI Cancer Stem Cell RFA section	National Institutes of Health
2008	Myeloma Research Foundation RFA study section on cancer stem cells	
2008-2009	National Cancer Institute of Canada, Chair, program project grant review panel.	
2011-2015	ACS Council for Extramural Grants	
2013	Cancer Pathology (CAMP) study section	National Institutes of Health
2014	Terry Fox Research Institute Program Project Grant Panel	
2015-18	Member, CAMP study section	National Institutes of Health
2018	NCI PAR-18-552 U01 panel	
2019-21	Chair, CAMP study section	National Institutes of Health
2022	Leukemia and Lymphoma Society, SCOR	Chicago, IL
2023	Leukemia and Lymphoma Society, CDP	Newark, NJ
2023	NCI, R35 review panel	virtual
2024	Leukemia and Lymphoma Society, CDP	Newark, NJ
2024	Leukemia and Lymphoma Society, SCOR	Chicago, IL
2024	NCI P01 study section	virtual

**Journal and Society Review:**

1996-present	Ad Hoc reviewer	<i>Blood</i>
1996-present	Ad Hoc reviewer	<i>Experimental Hematology</i>
2001-present	Ad Hoc reviewer	<i>Nature Medicine</i>
2002-present	Ad Hoc reviewer	<i>Molecular Therapy</i>
2003-present	Ad Hoc reviewer	<i>Leukemia Research</i>
2004-present	Ad Hoc reviewer	<i>Cancer Cell</i>
2006-present	Ad Hoc reviewer	<i>PNAS</i>
2006-present	Ad Hoc reviewer	<i>Nature</i>
2006-present	Ad Hoc reviewer	<i>Nature Genetics</i>
2005-present	Ad Hoc reviewer	American Soc. Hematology Mtg Annual Meeting Abstracts
2007-present	Ad Hoc reviewer	<i>Cell Stem Cell</i>
2007-present	Ad Hoc reviewer	<i>Science</i>
2009-present	Ad Hoc reviewer	<i>Science Translational Medicine</i>
1998, 2000	Ad Hoc reviewer	<i>Journal of Leukocyte Biology</i>
1999-2000	Ad Hoc reviewer	<i>Human Gene Therapy</i>
1999-2000	Ad Hoc reviewer	<i>Biology of Blood &amp; Marrow Transplantation</i>
2001-2002	Ad Hoc reviewer	<i>Journal of Immunology</i>
2001-2003	Ad Hoc reviewer	<i>Haematologica</i>
2001-2002	Ad Hoc reviewer	<i>Cancer Research</i>
2002, 2004	Ad Hoc reviewer	<i>Gene Therapy</i>

2002, 2005	Ad Hoc reviewer	<i>Journal of Clinical Investigation</i>
2002, 2003	Ad Hoc reviewer	<i>Journal of Gene Medicine</i>
2003	Ad Hoc reviewer	<i>BioEssays</i>
2003, 2005	Ad Hoc reviewer	<i>Nature Reviews Cancer</i>
2004	Ad Hoc reviewer	<i>Lancet</i>
2004, 2009	Ad Hoc reviewer	<i>Nature Biotechnology</i>
2004	Ad Hoc reviewer	<i>Carcinogenesis</i>
2004	Ad Hoc reviewer	<i>Trends in Immunology</i>
2005	Ad Hoc reviewer	<i>Clinical Cancer Research</i>
2006	Ad Hoc reviewer	<i>Nature Reviews Drug Discovery</i>
2007, 2019	Ad Hoc reviewer	<i>New England Journal of Medicine</i>
2008	Ad Hoc reviewer	<i>Journal of Experimental Medicine</i>
2011	Ad Hoc reviewer	<i>Drug Discovery Today</i>
2012	Ad Hoc reviewer	<i>Nature Communications</i>
2018	Ad Hoc reviewer	<i>Cancer Discovery</i>
2019	Ad Hoc reviewer	<i>Nature Metabolism</i>

### **11. Invited extramural lectures**

1996	International Society of Experimental Hematology Meeting, New York, NY.
1996	Keystone Symposia - Stem Cell Gene Therapy Conference
1996	University of North Carolina – Gene Therapy Center
1997	St. Jude Childrens Research Hospital - Molecular and Cellular Biology Dept.
1997	Harvard Medical School – Dana Farber Cancer Institute
1997	Duke University Medical School - Division of Oncology and Bone Marrow Transplant
1998	Keystone Symposia - Stem Cell Gene Therapy Conference
1998	Ninth International Symp. on Autologous Bone Marrow Transplantation, Dallas TX.2
1999	American Society of Hematology Meeting – New Orleans, LA
2000	University of Kentucky - Department of Biology Seminar Series
2000	University of Kentucky – Department of Medicine, Grand Rounds
2000	MD Anderson Cancer Center, Houston, TX
2000	Duke University Medical School - Division of Oncology and Bone Marrow Transplant
2000	Princeton University Molecular Biology Symposium, Princeton, N.J.
2000	Leukemia and Lymphoma Society, Translational Research Meeting, Wash. D.C.
2000	Sixth annual meeting of the International Society for Hematotherapy and Graft Engineering, San Diego, CA.
2001	Sidney Kimmel Cancer Center, San Diego, CA.
2001	Childrens Hospital, Los Angeles, CA.
2002	University of Pennsylvania Medical Center, Pennsylvania, PA.
2002	University of Louisville, Institute for Cellular Therapeutics
2002	Duke University Medical School – Department of Medicine
2002	University of Iowa Medical Center, Iowa City, Iowa
2002	University of New Mexico Cancer Center, Albuquerque, New Mexico
2002	University of New Mexico Medical Center, Albuquerque, New Mexico
	Dept. of Medicine Grand Rounds
2002	American Society of Hematology Meeting – Philadelphia, PA.
2003	University of Rochester Medical Center, Rochester, New York
2003	Washington University Medical Center, St. Louis, Missouri
2003	Indiana University Medical Center, Indianapolis, Indiana

2003 Erasmus Workshop on Molecular Therapeutics in Acute Leukemia – Rotterdam, NL  
 2003 American Society of Gene Therapy Meeting, Washington, D.C.  
 2004 American Society of Gene Therapy Meeting, Minneapolis, MN  
 2004 Leukemia and Lymphoma Society Workshop - Ontario, Canada  
 2004 American Society of Hematology – Education Session, San Diego, CA.  
 2005 Amgen Symposium on Hematologic Malignancies, Hollings Cancer Center, Medical University of South Carolina  
 2005 University of Montreal, Montreal, Canada  
 2005 University of Pittsburgh Cancer Institute, Hillman Cancer Center, Pittsburgh PA.  
 2005 Children’s Hospital of Philadelphia, summer retreat, *keynote speaker*.  
 2005 International Workshop on Cancer Stem Cells, Milan, Italy.  
 2005 Banbury Conference on Cancer Stem Cells, Cold Spring Harbor  
 2006 American Associate for Cancer Research (AACR), Washington D.C.  
 Cancer Stem Cells Workshop  
 2006 Acute Leukemia Forum, San Francisco, CA  
 2006 American Associate for Cancer Research (AACR), Washington D.C.  
 Annual Meeting  
 2006 Amgen, Inc, Thousand Oaks, CA  
 2006 University of California, San Francisco, CA  
 2006 International Society for Experimental Hematology – Minneapolis, MN  
*Plenary session*  
 2006 Pediatric Academic Societies Annual Meeting, San Francisco, CA  
 2006 Eugene Cronkite Memorial Symposium, Brookhaven National Laboratory  
 2006 University of Maryland Cancer Center, Baltimore, MD  
*“Frontiers in Oncology” lecture*  
 2006 American Society of Hematology Meeting, Orlando, FL  
 2007 BMT Tandem Meeting, Keystone Colorado, *Plenary Session*  
 2007 Loyola University Cancer Center, Chicago, IL, *Basic Science Seminar Series*  
 2007 Vanderbilt University, Nashville, TN  
 2007 American Association of Cancer Research, annual meeting, Los Angeles, CA  
 2007 Gordon Conference, “Stem Cells and Cancer”, Big Sky, Montana  
 2007 Leukemia and Lymphoma Society Translational Research Meeting, NYC  
 2007 Albert Einstein College of Medicine, New York  
 2007 AACR/NCI, “Molecular Targets and Cancer Therapeutics”, *plenary session*  
 2007 University of British Columbia, Terry Fox Laboratory, Vancouver  
 2007 Fox Chase Cancer Center, Philadelphia, PA  
 2007 American Society of Hematology Meeting, Atlanta, GA – *Presidential Symposium*  
 2007 Leukemia and Lymphoma Society, Stohlman Scholar Symposium, Anaheim, CA  
 2008 Radiation Therapy Oncology Group (RTOG) meeting – Translational Research Symp.  
 2008 Multiple Myeloma Research Foundation, New York City, Cancer Stem Cell Workshop  
 2008 Moffit Cancer Center, Tampa, FL, Grand Rounds  
 2008 Molecular Medicine Tri-Conference, San Francisco, Cancer Stem Cells short course  
 2008 MD Anderson, Cancer Stem Cell Retreat, Houston, TX – *Keynote speaker*  
 2008 Acute Leukemia Forum, San Francisco, CA.  
 2008 Wales Cancer Conference, Cardiff, United Kingdom  
 2008 Cincinnati Children’s Hospital, Hematology Oncology Seminar Series  
 2008 ISSCR, Philadelphia, PA – *Plenary Session*  
 2008 Seventh International Congress on Targeted Therapies in Oncology, Washington, D.C.  
 2008 AACR, Molecular Diagnostics in Cancer Therapeutic Development, Philadelphia, PA  
 2008 Weill Cornell Medical College, Pharmacology Seminar Series, NY, NY

2008 Kimmel Cancer Center, Oncology Grand Rounds, Philadelphia, PA  
 2008 Leukemia Society Stohlman Symposium, Kansas City, KC - *Speaker and session chair*  
 2009 Epigenetics in Cancer Therapy Meeting, Coral Gables, FL  
 2009 Baylor College of Medicine, Houston, CAGT seminar series.  
 2009 Duke University, Stem Cell Institute Lecture Series  
 2009 Roswell Park Cancer Institute, Microbiology and Cancer Biology seminar series  
 2009 AACR meeting, "State-of-the-Art Pathophysiology and Therapy of AML", Denver CO  
 2009 New York Cancer Consortium Symposium, NY City, NY  
 2009 Hematology Grand Rounds, MD Anderson Cancer Center, Houston, TX  
 2009 14<sup>th</sup> Mayo-Luther Forum on Hematopoietic and Stem Cells, Mayo Clinic, MN  
 2009 FASEB, Hematologic Malignancies Meeting, Vermont  
 2009 8<sup>th</sup> International Congress on Targeted Therapies for Cancer, Washington DC  
 2009 IACRLRD Symposium XXIV, Columbus, OH  
 2009 12<sup>th</sup> International Conference on Differentiation Therapy, Chicago, IL  
 2009 American Society of Hematology Meeting, New Orleans, LA – Scientific Committee on Myeloid Neoplasia.  
 2009 Memorial Sloan Kettering Cancer Center, Molecular Pharmacology Seminar Series  
 2010 City of Hope Cancer Center, Grand Rounds, Los Angeles, CA.  
 2010 University of North Carolina, Cancer Center Seminar, Chapel Hill, NC.  
 2010 ISSCR Meeting, San Francisco, CA.  
 2010 University of Minnesota, Center for Drug Design, Lecture Series  
 2010 Cleveland Clinic, Stem Cell Biology Lecture Series  
 2010 New Jersey Cancer Institute, Grand Rounds  
 2011 Baylor/M.D. Anderson Symposium: Stem Cells and Cancer – keynote speaker  
 2011 Gordon Conference, Stem Cells and Cancer, invited speaker  
 2011 Vanderbilt University, Biochemistry Dept. Seminar, Nashville, TN  
 2011 Keystone Symposium, Hematopoiesis, invited speaker  
 2011 Harvard Stem Cell Symposium, Harvard Medical School, Boston, MA  
 2011 Roswell Park Cancer Institute, Medical Grand Rounds, Buffalo, NY  
 2012 Purdue University, Cancer Center Grand Rounds, West Lafayette, IN  
 2012 Penn State University, State College, PA  
 2012 Cancer Stem Cell Symposium, University of Pennsylvania, Philadelphia, PA  
 2012 Acute Leukemia Forum, San Francisco, CA  
 2012 9<sup>th</sup> International Workshop on Molecular Aspects of Myeloid Stem Cell Development and Leukemia, Cincinnati, OH  
 2012 Japanese Hematology Society Meeting – 3<sup>rd</sup> International Symposium, Kawagoe, Japan  
 2012 Cancer Center Grand Rounds - Oregon Health Sciences University, Portland, OR  
 2012 Mt Sinai School of Medicine – Stem Cell Seminar Series, NY, NY  
 2012 Scripps Research Institute, Research Seminar, Jupiter, FL  
 2012 University of Miami, Cancer Center Grand Rounds, Miami, FL  
 2013 Judy Karp Symposium on Acute Leukemia, Baltimore  
 2013 University of Colorado Cancer Center, Grand Rounds  
 2013 NCI Workshop on Oncolytic Viruses, Wash DC  
 2013 American Chemical Society Meeting, Indianapolis, IN  
 2014 Keystone Symposium, Cancer and Stem Cells, Banff  
 2014 10<sup>th</sup> International Workshop on Molecular Aspects of Myeloid Stem Cell Development and Leukemia, Cincinnati, OH  
 2014 European Society of Hematology, CML Meeting, Philadelphia  
 2014 Jonah Platt Stem Cell Lecture Series, UCSF, San Francisco  
 2015 Edward P. Evans Foundation Annual Meeting, Washington DC



2015 Hematology Research Conference, University of Utah  
 2016 Grand Rounds, Moffitt Cancer Center, FL  
 2016 Hematology Grand Rounds, Mayo Clinic, Rochester, MN  
 2016 Myeloid Stem Cell Meeting, Cincinnati, OH  
 2016 Edward P. Evans Fdn Annual Mtg, Nashville, TN  
 2018 Research Seminar, Abbvie Inc., Chicago IL  
 2018 Leukemia and Lymphoma Society Mtg, Philadelphia, PA  
 2019 Acute Leukemia Forum, Newport Beach, CA  
 2019 Forbeck Foundation Meeting, Denver, CO  
 2019 Leukemia and Lymphoma Society Mtg, NY, NY  
 2020 Memorial Sloan Kettering, Hematologic Malignancies conf., NY (virtual)  
 2020 Emory, Winship Cancer Institute Retreat, GA (virtual)  
 2021 Frontiers in Blood, Cancer, and Development (virtual)  
 2021 Lurie Cancer Center Symposium Keynote address (virtual)  
 2021 University of Heidelberg (virtual)  
 2021 Baylor College of Medicine (virtual)  
 2021 Japanese Society of Hematology Mtg (virtual)  
 2021 Keynote, Canceropole Mini Symposium on Residual Disease in Cancer (virtual)  
 2021 Keynote, John Goldman CML Mtg (virtual)  
 2021 Johns Hopkins Visiting Professorship (virtual)  
 2021 University of Pennsylvania Distinguish Lectures in Cancer Research (virtual)  
 2021 Keynote, Francis Crick Institute Annual Molecular Haemopoiesis Mtg (virtual)  
 2022 University of Chicago (virtual)  
 2023 Cancer Metabolism Meeting, Zhedong, China (virtual)  
 2023 St. Jude Childrens Research Hospital (virtual)  
 2023 Leukemia and Lymphoma Society Mtg, NY, NY  
 2024 Columbia University Medical Center, NY  
 2024 14<sup>th</sup> International Workshop on Molecular Aspects of Myeloid Stem Cell Development and Leukemia, Cincinnati, OH  
 2024 Leukemia and Lymphoma Society Mtg, NY, NY

## **12. Teaching Record**

### **Courses/Lectures**

1. Co-director and lecturer Hem/Onc Fellows research seminar series, 1999-2003.
2. Lecturer, Pharmacy 647 course, 1998-2001.
3. Lecturer, Micro/Immunology 615 course, 1999-2003.
4. Lecturer, Undergraduate Virology seminar, 1999-2000.
5. Co-director and lecturer, Micro/Immunology 707 course, 2000.
6. Lecturer, IBS 602 course, 2001-2003
7. Lecturer, MI 816 course, 2002
8. Molecular Biology Journal Club, 1998-2000.
9. Bone Marrow Transplant Journal Club, 1998-2001.
10. Kentucky Appalachian Science Enrichment Program (KASEP), 2001-2002
11. Faculty, UK Mini-Med School, 2002
12. Lecture, Model High School Students, 2002
13. UK Freshman Discovery Seminar, 2002
14. URM, Medical school course "Process of Discovery", 2004-2006
15. URM, MD/PhD course "Scientific Reasoning in Medicine", 2004

16. UPMC, Clinical Research Curriculum Series, 2005
17. UPMC, Life Sciences Learning Center Workshop, 2005
18. UPMC, IND409, graduate cell biology course, 2005-2013
19. UPMC, PTH507, graduate cancer biology course, 2006-2013
20. MSTP graduate course, M2M, 2020
21. Cancer Biology program, grant-writing course, 2022-2023

### **Graduate Students:**

	<u>Current position</u>
1. Ph.D. advisor, Monica Guzman, 1998-02.	Assoc. Prof., Cornell Med. School, NY, NY
2. Ph.D. advisor, Selcuk Sozer, 2000-2004.	Asst. Prof., Dept of Genetics, Istanbul University, Turkey
3. Ph.D. advisor, Pin-Yi Wang, 2004-2007	Post-doc fellow, Cincinnati Childrens Hospital
4. Ph.D. advisor, John Ashton, 2005-2011	Director, Functional Genomics Univ. of Rochester
5. Ph.D. advisor, Shanshan Pei, 2008-2013	Research Asst Professor, University of Colorado
6. M.S. advisor, Alexander Sach, 2012-2013	Graduate school, Germany
7. Ph.D. advisor, Haobin Ye, 2012-2017	Professor, Fudan University, China
8. Ph.D. advisor, Jessica Ponder, 2013-2018	Staff, Physicians Com. for Responsible Medicine
9. Ph.D. advisor Biniam Adane, 2013-2018	Post-doc, Harvard (mentor, Kim Stegmaier)
10. Ph.D. advisor, Anagha Inguva, 2018-2023	Completing MSTP clinical training at CU
11. Ph.D. co-advisor, Rachel Culp-Hill, 2019-23	Research Associate, Univ of Colorado
12. Ph.D. advisor, Ian Shelton, 2021-2024	Senior Researcher, Refined Sciences Inc.
13. Ph.D. advisor, Regan Miller, 2021-present	

### **Post-Doctoral Fellows and Instructors:**

	<u>Current position</u>
1. Dr. Dianna Howard, 1997-1998.	Professor, Wake Forrest Univ, Winston-Salem, NC
2. Dr. Shifu Zhao, 1997-1999.	Associate Professor, Beijing Institute of Radiation Medicine
3. Dr. Marcie Riches (nee Tomblyn), 1999-2000.	Associate Member, Moffitt Cancer Center, FL
4. Dr. Deborah Echlin, 2001-2003.	Eli Lilly, Sr. Scientific Communications Associate
5. Dr. Monica Guzman, 2002-2009.	Assoc. Prof, Weill Cornell Medical School, NY
6. Dr. Anthony Bibawy, 2004-2005	Greek Orthodox Seminary, Rochester, NY
7. Dr. Elie Dib, 2005-2006	Deputy PI, Michigan Cancer Res. Consortium, NCORP, MI
8. Dr. Duane Hassane, 2005-2009	Res. Asst. Prof, Weill Cornell Medical School, NY
9. Dr. Sidhartha Sen, 2006-2009	Assistant Professor, Univ of Minnesota, MN
10. Dr. Christina Wiedl, 2008-2011	Assistant Professor, Virginia Commonwealth Univ.
11. Dr. Kristen O'Dwyer, 2010-2012	Assoc Professor, University of Rochester, NY
12. Dr. Kevin Callahan, 2008-2013	Assoc Professor, St. John Fisher College, Rochester, NY
13. Dr. Eleni Lagadinou, 2011-2013	Oncology Clinical Leader, Bayer AG, Berlin
14. Dr. Shanshan Pei, 2013-2018	Principal Investigator, Zhejiang Univ Medical Ctr, China
15. Dr. Brett Stevens, 2013-2015	Research Asst Professor, University of Colorado
16. Dr. Amanda Winters, 2015-2018	Asst Professor, University of Colorado
17. Dr. Maria Amaya, 2018-2020	Staff Physician, Eastern Colorado VA
18. Dr. Courtney Jones, 2016-2020	Assistant Professor, University of Toronto
19. Dr. Jessica Ponder, 2018-2020	Staff, Physicians Committee for Responsible Medicine
20. Dr. Haobin Ye, 2016-2020	Professor, Fudan University, Shanghai, China
21. Dr. Jordan Althoff, 2020-present	
22. Dr. Sweta Patel, 2021-present	

23. Dr. Ana Vujovic, 2023-present

**Ph.D. Thesis Committees:**

1. Cameron Dingle, Dept. of Microbiology/Immunology/Molecular Genetics, Univ. of Kentucky
2. Zhengrong Cui, Division of Pharmaceutical Sciences, University of Kentucky
3. Sudhir Perincheri, Dept. of Microbiology/Immunology/Molecular Genetics, Univ. of Kentucky
4. Sajni Jossen, Dept. of Toxicology, University of Kentucky
5. Karah Nazor, Program in Gerontology, University of Kentucky
6. Mingdong Liu, Biomedical Engineering Department, University of Kentucky
7. Kathleen Nichol, Dept. of Microbiology/Immunology/Molecular Genetics, Univ. of Kentucky
8. Jeffrey Yates, Dept. of Physiology, University of Kentucky
9. Meredith Bostrom, Program in Nutrition, University of Kentucky
10. Craig Dorrell, Molecular and Medical Genetics, University of Toronto
11. Jonathan Pollett, Molecular and Medical Genetics, University of Toronto
12. Amber Wyman, Dept. of Environmental Medicine, University of Rochester (Chair)
13. Wanchang Cui, Biomedical Genetics Dept., University of Rochester (Chair)
14. Pin-Yi Wang, Dept of Pathology, University of Rochester
15. Nichola Charles, Biomedical Engineering Dept, University of Rochester
16. Megan Enos, Dept. of Immunology, University of Rochester
17. Alayna Loiselle, Orthopedics Dept., University of Rochester
18. Jun Wang, Biomedical Genetics Dept., University of Rochester
19. Conan Kinsey, Biomedical Genetics Dept., University of Rochester
20. Fanny Casado, Dept. of Environmental Medicine, University of Rochester
21. Brett Stevens, Pharmacology & Physiology Dept, University of Rochester
22. Jobie McKenzie, University of Toronto, external examiner
23. Zuzana Tothova, Harvard Medical School, external examiner
24. Rosemarie Marchan, Dept of Environmental Medicine, University of Rochester (Chair)
25. Veena Ganeshan, Neuroscience program, University of Rochester
26. Hsing-Yu (Warner) Chen, Biomedical Genetics Dept., University of Rochester
27. Vijaya Balakrishnan, Biomedical Genetics Dept., University of Rochester
28. Jordan Aldersley, Biomedical Genetics Dept., University of Rochester
29. Aslihan Petenkaya, Biomedical Genetics Dept., University of Rochester
30. Julie Babulski, Biomedical Genetics Dept., University of Rochester
31. Sayak Ghatak, Biology Dept, University of Rochester
32. Michael Baranello, Dept of Chemical Engineering, University of Rochester
33. Michael Wilson, Dept of Pathology, University of Rochester
34. Jennifer Stripay, Biomedical Genetics Dept, University of Rochester
35. Gregory Kirkpatrick, Cancer Biology Program, University of Colorado
36. Catherine Pham-Danis, Cancer Biology Program, University of Colorado
37. Kelly Higa, Immunology Program, University of Colorado
38. Molly Kingsley, Molecular Biology Program, University of Colorado
39. Travis Nemkov, Molecular Biology and Biochemistry, University of Colorado
40. Kim Casalvieri, Pharmaceutical Sciences, University of Colorado
41. Hae Park, Medical Scientist Training Program, University of Colorado
42. Marlie Fisher, Medical Scientist Training Program, University of Colorado
43. Taylor Mills, Immunology Program, University of Colorado
44. Rachel Hill, Molecular Biology and Biochemistry, University of Colorado
45. Lorraine Davis, Cancer Biology Program, University of Colorado
46. Connor Purdy, Cancer Biology Program, University of Colorado
47. Wolfgang Schleicher, Molecular Biology and Biochemistry, Univ. of Colorado

48. Juliet Mullen, Pharmaceutical Sciences, University of Colorado
49. Daniela Ortiz Chavez, Cancer Biology, University of Colorado
50. Spencer Hall, Pharmacology Graduate Program, University of Colorado
51. Amandip Bangar, Medical Scientist Training Program, University of Colorado

### **13. Other Advising Activities:**

52. Mentor, Dr. Dianna Howard, American Society of Clinical Hematology Young Investigator Award, 1998-99.
53. Mentor, Dr. Dianna Howard, University of Kentucky Physician Scientist Award, 1999-2002.
54. Mentor, three graduate students for MI-772 seminars, 1999-2001.
55. Mentor, graduate student laboratory rotation projects (1-3 students/yr.), 1998-present.
56. Mentor undergraduate students (1-2 students each year), 1999-present.

### **14. Grant Support**

#### **Active Grants:**

1. PI: Craig T. Jordan  
 Title: Therapeutic Targeting of AML Stem Cells  
 Agency: Leukemia and Lymphoma Society (SCOR grant)  
 Period: 10/01/23-9/30/28  
 Award: \$4,165,000 (total direct costs)
  
2. PI: Craig T. Jordan  
 Title: Therapeutic Targeting of MDS Stem Cells  
 Agency: VA Merit Award BX004768-01  
 Period: 04/01/20-03/31/24 (no cost extension to 03/31/25)  
 Award: \$1,050,916 (total direct costs)
  
3. PI: Craig T. Jordan  
 Title: Therapeutic Targeting of Human AML Stem Cells  
 Agency: NIH/NCI (R35CA242376)  
 Period: 09/15/20-08/31/27  
 Award: \$3,812,441 (total direct costs)
  
4. PI: Craig T. Jordan  
 Title: Modeling LSC heterogeneity at unprecedented resolution in AML  
 Agency: Leukemia and Lymphoma Society (Discovery grant)  
 Period: 10/01/24-9/30/27  
 Award: \$637,500 (total direct costs)
  
5. PI: Craig T. Jordan  
 Title: Targeting mitochondrial calcium to eradicate leukemia-initiating cells  
 Agency: NIH/NCI (R01CA292071)  
 Period: 08/01/24-07/31/29  
 Award: \$1,402,025 (total direct costs)

6. PI: Daniel Pollyea (C. Jordan, Co-PI)  
Title: Lower-dose mitoxantrone for eradication of AML-associated leukemic stem cells with metabolic resistance to venetoclax plus hypomethylating agent therapy  
Agency: Leukemia and Lymphoma Society (Academic Clinical Trials grant)  
Period: 10/01/24-9/30/27  
Award: \$850,000 (total direct costs)

**Completed projects:**

1. PI: Craig T. Jordan  
Title: "A Gene Transfer Vector for Quiescent Stem Cells"  
Agency: NIH/NIDDK (SBIR grant)  
Period: 1996 (one year)  
Award: \$100,000
2. PI: Craig T. Jordan  
Title: "Novel Gene Therapy Strategy for the Generation of Leukemia Vaccines"  
Agency: Leukemia and Lymphoma Society (formerly Leukemia Society)  
Period: 9/1/98-8/31/01  
Award: \$324,000
3. PI: Craig T. Jordan  
Title: "A novel antibody-based immunotherapy treatment for AML"  
Agency: National Leukemia Research Association  
Period: 1/1/01-12/31/01  
Award: \$20,000
4. PI: Craig T. Jordan  
Title: "Antigenic and molecular characterization of human leukemic stem cells"  
Agency: American Cancer Society Research Project Grant (RPG-99-206-01-LBC)  
Period: 7/1/99-6/30/02  
Award: \$436,000
5. PI: Craig T. Jordan  
Title: "Molecular Characterization of Human Hematopoietic Stem Cells"  
Agency: NIDDK/NIH (subcontract for R01-DK54493, Ihor Lemischka - PI)  
Period: 7/1/98-6/30/02  
Award: \$125,256
6. PI: Craig T. Jordan  
Title: "Novel immunotherapy approaches for AML"  
Agency: Deltagen, Inc.  
Period: 2/9/01-2/8/03  
Award: \$362,222

7. PI: Stephen J. Szilvassy  
Co-investigator: Craig T. Jordan  
Title: "Engraftment studies of expanded hematopoietic stem cells"  
Agency: NHLBI/NIH (R01-HL61392)  
Period: 7/1/99-6/30/03  
Award: 5% salary support for C. Jordan
8. PI: Deneys van der Westhuyzen  
Co-investigator: Craig T. Jordan  
Title: "SR-BI: Influence of Apo AII"  
Agency: NIH/NHLBI (R01 HL65730)  
Period: 9/15/00-8/31/03 (5% salary support for C. Jordan)
9. PI: Craig T. Jordan  
Title: "Malignant stem cells in leukemia and solid tumors"  
Agency: Leukemia and Lymphoma Society Special Workshop Grant  
Period: 5/04  
Award: \$30,000
10. PI: Craig T. Jordan  
Title: "Properties of Leukemia Stem Cells in a Novel Model of CML Progression to Lymphoid Blast Crisis"  
Agency: U.S. Department of Defense (CM050044)  
Period: 1/1/06-12/31/06  
Award: \$149,707
11. PI: Craig T. Jordan  
Title: "Targeted ablation of CML stem cells"  
Agency: U.S. Department of Defense (DAMD17-03-1-0263)  
Period: 4/15/03-4/14/07  
Award: \$748,915
12. PI: Dianna S. Howard  
Co-PI: Craig T. Jordan (subcontract)  
Title: "Bortezomib and Idarubicin in the Treatment of AML"  
Agency: NIH/NCI (R21-CA108162)  
Period: 9/20/04-8/31/07  
Award: \$173,062
13. PI: Craig T. Jordan  
Title: "Cellular and molecular studies of leukemic stem cells"  
Agency: NIH/NCI (R01-CA90446)  
Period: 12/01/01-11/30/07  
Award: \$1,288,720
14. PI: Craig T. Jordan  
Title: "An in vivo model for leukemic stem cells"  
Agency: American Cancer Society Research Scholar Grant (RSG-03-096-01-LIB)  
Period: 1/01/03-12/31/07  
Award: \$734,000

15. PI: Craig T. Jordan  
 Title: "Molecular genetic analysis of mechanisms controlling apoptosis in LSC"  
 Agency: Leukemia and Lymphoma Society Scholar Award  
 Period: 7/1/03-6/30/08  
 Award: \$500,000
16. PI: Craig T. Jordan  
 Title: "Imagestream Flow Cytometer"  
 Agency: NIH – shared instrumentation grant  
 Period: 12/1/07  
 Award: \$407,000
17. PI: Craig T. Jordan  
 Title: "Differentiation therapy & epigenetic modulation of leukemia stem cells"  
 Agency: Waxman Foundation  
 Period: 7/1/07-6/30/09  
 Award: \$200,000
18. PI: Craig T. Jordan  
 Title: "Novel strategies to specifically target leukemia stem cells"  
 Agency: Leukemia and Lymphoma Society Translational Grant  
 Period: 10/1/05-9/30/10  
 Award: \$957,645
19. PI: Craig T. Jordan  
 Title: "A novel thiadiazolidine-dione targets human leukemia stem cells"  
 Agency: Leukemia and Lymphoma Society Translational Grant  
 Period: 10/1/07-9/30/10  
 Award: \$600,000
20. PI: Craig T. Jordan  
 Title: "Selective in vivo ablation of leukemia stem cells"  
 Agency: NIH/NCI (R01-CA122206)  
 Period: 7/01/07-6/30/11  
 Award: \$750,000
21. PI: Craig T. Jordan  
 Title: "Therapeutic targeting of leukemia stem cells"  
 Agency: NY State Stem Cell Foundation (C024964)  
 Period: 1/1/09-06/30/12 (No cost extension)  
 Award: \$1,079,790
22. PI: Richard I. Fisher (C. Jordan, PI for project #4)  
 Title: "SPORE in Lymphoma"  
 Agency: NCI/NIH (P50CA130805)  
 Period: 7/1/08-6/30/12  
 Award: \$960,383 (Project #4 budget)

23. PI: Richard Fisher (C. Jordan, PI for project #1)  
 Title: Early Diagnosis, Treatment and Care of Cancer Patients  
 Agency: Department of Defense (W81XWH-07-1-0601)  
 Period: 1/1/08-12/31/12  
 Award: \$1,060,000 (project #1 budget)
24. PI: Craig T. Jordan  
 Title: "Optimized strategies for therapeutic targeting of leukemia stem cells"  
 Agency: Leukemia and Lymphoma Society Translational Grant (6230-11)  
 Period: 10/1/10 – 9/30/13  
 Award: \$600,000
25. PI: Craig T. Jordan  
 Title: "Modulating oxidative state to target leukemia stem cells"  
 Agency: Leukemia and Lymphoma Society Translational Grant (6133-12)  
 Period: 10/1/11 – 9/30/14  
 Award: \$600,000 (total costs)
26. PI: Rudi Fasan (co-investigator, Craig T. Jordan)  
 Title: Novel chemical agents to target and eradicate leukemia stem cells  
 Agency: Leukemia and Lymphoma Society Translational Grant (6116-14)  
 Period: 10/1/13-9/30/16  
 Award: \$600,000 (total costs) (\$210,000 budgeted to C. Jordan)
27. PI: Peter Crooks (co-investigator, Craig T. Jordan)  
 Title: "Novel melampomagnolide B-based prodrugs for the treatment of leukemia"  
 Agency: NIH/NCI (R01CA158275)  
 Period: 1/01/12-12/31/16  
 Award: \$1,320,000 (direct costs) (50% budgeted to C. Jordan)
28. PI: Craig T. Jordan  
 Title: Characterization and targeting of MDS stem cells  
 Agency: Edward P Evans Foundation  
 Period: 9/01/15-8/31/17  
 Award: \$400,000 (total costs)
29. PI: Craig T. Jordan  
 Title: Analysis of AML stem cell targeting for SGN-CD123A  
 Agency: Seattle Genetics  
 Period: 05/01/16 – 4/30/18  
 Award: \$149,375 (total costs)
30. PI: Craig T. Jordan  
 Title: "Oncogene cooperativity in leukemia stem cells"  
 Agency: NIH/NCI (R01CA166265)  
 Period: 6/1/12-05/30/18 (NCE)  
 Award: \$1,037,500 (total direct costs)



31. PI: Dan Theodorescu (program co-leader, Craig T. Jordan)  
 Agency: NIH/NCI (5P30CA046934)  
 Period: 04/04/97-01/31/22  
 Award: \$2,548,376 (annual direct costs)
32. PI: Craig T. Jordan  
 Title: Adoptive CD123 CAR T-cell therapy for the treatment of MDS  
 Agency: Edward P Evans Foundation  
 Period: 9/01/16-8/31/20  
 Award: \$800,000 (total direct costs)
33. PI: Craig T. Jordan  
 Title: Microenvironment-induced metabolic plasticity in leukemia stem cells  
 Agency: NIH/NCI (R01220986)  
 Period: 12/06/17-11/30/22 (exchanged for R35CA242376 in 2020)  
 Award: \$1,143,750 (total direct costs)
34. PI: Craig T. Jordan  
 Title: "Venetoclax-based targeting of leukemia stem cells"  
 Agency: NIH/NCI (R01)  
 Period: 12/1/19-11/30/24 (exchanged for R35CA242376 in 2020)  
 Award: \$1,156,340 (total direct costs)
35. PI: Craig T. Jordan  
 Title: "Characterization and Targeting of Leukemia Stem Cell Metabolism"  
 Agency: NIH/NCI (R01CA200707)  
 Period: 7/1/16-6/30/21  
 Award: \$1,500,325 (total direct costs)
36. PI: Craig T. Jordan  
 Title: Therapeutic Targeting of AML Stem Cells  
 Agency: Leukemia and Lymphoma Society (SCOR grant)  
 Period: 10/01/18-9/30/23  
 Award: \$4,165,000 (total direct costs)

## **15. Bibliography**

**Complete list of published works in MyBibliography:**

<http://www.ncbi.nlm.nih.gov/myncbi/browse/collection/44657234/?sort=date&direction=descending>

### **Peer-Reviewed Primary Research Manuscripts:**

1. **Jordan, C.T.**, and Lemischka, I.R. (1990). Clonal and systemic analysis of long-term hematopoiesis in the mouse. *Genes Dev* 4:220-232. [PMID:1970972](#).
2. **Jordan, C.T.**, McKearn, J.P., and Lemischka, I.R. (1990). Cellular and developmental properties of fetal hematopoietic stem cells. *Cell* 61:953-963. [PMID:1972037](#).

3. Matthews, W., **Jordan, C.T.**, Weigand, G.W., Pardoll, D., and Lemischka, I.R. (1991). A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell enriched populations. *Cell* 65:1143-1152. [PMID:1648448](#).
4. Matthews, W., **Jordan, C.T.**, Gavin, M., Jenkins, N.A., Copeland, N.G., and Lemischka, I.R. (1991). A new receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit. *PNAS* 88:9026-9030. [PMID:1717995](#).
5. Harrison, D.E., **Jordan, C.T.**, Zhong, R.K., and Astle, C.M. (1993). Primitive hemopoietic stem cells: direct assay of most productive populations by competitive repopulation with simple binomial, correlation and covariance calculations. *Exp. Hematol.* 21:206-219. [PMID:8425559](#).
6. Zeigler, F.C., Bennett, B.D., **Jordan, C.T.**, Spencer, S.D., Baumhueter, S., Carroll, K.J., Hooley, J., Bauer, K., and Matthews, W. (1994). Cellular and molecular characterization of the role of the FLK-2/FLT-3 receptor tyrosine kinase in hematopoietic stem cells. *Blood*, 84(8):2422-2430. [PMID:7919361](#).
7. **Jordan, C.T.**, Astle, C.M., Zawadzki, J., Mackarehtschian, K., Lemischka, I.R., and Harrison, D.E. (1995). Long term repopulating abilities of enriched fetal liver stem cells measured by competitive repopulation. *Exp. Hematol.* 23:1011-1015. [PMID:7635180](#).
8. Neering, S.J., Hardy, S.F., Minamoto, D., Spratt, S.K., and **Jordan, C.T.** (1996). Transduction of primitive human hematopoietic cells with recombinant adenovirus vectors. *Blood* 88:1147-1155. [PMID:8695831](#).
9. **Jordan, C.T.**, Minamoto, D., and Yamasaki, G. (1996). High resolution cell cycle analyses of defined phenotypic subsets within human hematopoietic cell populations. *Exp. Hematol.* 24:1347-1355. [PMID:8862447](#).
10. Orlic, D., Girard, L.J., **Jordan, C.T.**, Anderson, S.M., Cline, A.P., and Bodine, D.M. (1996) The level of mRNA encoding the amphotropic retrovirus receptor in mouse and human hematopoietic stem cells is low and correlates with the efficiency of retrovirus transduction. *PNAS* 93:11097-11102. [PMID:8855315](#).
11. Orlic D., Bodine D.M., **Jordan C.T.**, Seidel N.E., Do B.K., Anderson S.M., Girard L.J. (1997). Transduction efficiency of cell lines and hematopoietic stem cells correlates with retrovirus receptor mRNA levels. *Stem Cells* 15 Suppl 1:23-29. [PMID:9368321](#).
12. Harrison, D.E., Zhong, R.K., **Jordan, C.T.**, Lemischka, I.R., and Astle, C.M. (1997). Relative to adult marrow, fetal liver repopulates nearly five times more effectively long term than short term. *Exp. Hematol.* 25:293-297. [PMID:9131003](#).
13. Bregni, M., Shammah, S., Malaffo, F., Di Nicola, M., Milanese, M., Magni, M., Matteucci, P., Ravagnani, F., **Jordan, C.T.**, Siena, S., and Gianni, A.M. (1998). Adenovirus vectors for gene transduction into mobilized blood CD34+ cells. *Gene Therapy* 5:465-472. [PMID:9614570](#).

14. Case, S.S., Price, M.A., **Jordan, C.T.**, Xu, D., Bauer, G., Yu, X.J., Wang, L., Verma, I.M., Naldini, L., Kohn, D.B., and Crooks, G.M. (1999). Stable transduction of quiescent CD34+CD38- human hematopoietic cells by HIV-1 based lentiviral vectors. *PNAS* 96:2988-2993. [PMID:10077624](#).
15. Rosenzweig, M., MacVittie, T., Harper, D., Hempel, D., Glickman, R., Johnson, R., Farese, A., Lind, L., Lyman, S., Theobald, N., Linton, G., **Jordan, C.T.**, and Malech, H. (1999). Efficient and persistent gene marking of hematopoietic progenitor cells in nonhuman primates. *Blood* 94:2271-2286. [PMID:10498599](#).
16. Howard, D.S., Rizzieri, D.A., Grimes, B., Upchurch, D., Phillips, G.L., Stewart, A.K., Yannelli, J.R., and **Jordan, C.T.** (1999). Genetic manipulation of primitive leukemic and normal hematopoietic cells using a novel method of adenovirus-mediated gene transfer. *Leukemia*, 13(10):1608-1616. [PMID:10516763](#).
17. Di Nicola M., Milanesi M., Magni M., Bregni M., Carlo-Stella C. Longoni P. Tomanin R., Ravagnani F., Scarpa, M., **Jordan C.**, and Gianni A.M. (1999). Recombinant adenoviral vector-lipofectamine complex for gene transduction into human T-lymphocytes. *Human Gene Therapy*, 10(11):1875-1884. [PMID:10446927](#).
18. **Jordan, C.T.**, Upchurch, D., Szilvassy, S.J., Guzman, M.L., Howard, D.S., Pettigrew, A.L., Meyerose, T., Rossi, R., Grimes, B., Rizzieri, D.A., Luger, S.M., and Phillips, G.L. (2000). The interleukin-3 receptor alpha chain is a unique marker for human acute leukemia stem cells. *Leukemia*, 14(10):1777-1784. [PMID:11021753](#).
19. Guzman, M.L., Upchurch, D., Grimes, B., Howard, D.S., Rizzieri, D.A., Luger, S.M., Phillips, G.L., and **Jordan, C.T.** (2001). Expression of Tumor Suppressor Genes IRF-1 and DAP-kinase in Primitive Acute Myelogenous Leukemia Cells. *Blood*, 97(7):2177-2179. [PMID:11264190](#).
20. Guzman, M.L., Neering, S.J., Upchurch, D. Grimes, B., Howard, D.S., Rizzieri, D.A., Luger, S.M., and **Jordan, C.T.** (2001). NF- $\kappa$ B is constitutively activated in primitive human acute myelogenous leukemia cells. *Blood - Plenary Paper*, 98(8):2301-2307. [PMID:11588023](#).
21. **Jordan, C.T.**, Vanin, E.F., and Marini, F.C. (2001) The use of adenoviral vectors for genetic manipulation and analysis of primitive hematopoietic cells. *Current Gene Therapy*, 1(3):257-266. [PMID:12109141](#).
22. Gong, S., Lu, X., Xu, Y., Swiderski, C.F., **Jordan, C.T.**, and Moscow, J.A. (2002) Identification of OCT6 as a novel organic cation transporter preferentially expressed in hematopoietic cells and leukemias. *Exp. Hematol.* 30:1162-1169. [PMID:12384147](#).
23. Guzman, M.L., Swiderski, C.F., Grimes, B.A., Howard, D.S., Rossi, R., Szilvassy, S.J., and **Jordan, C.T.** (2002). Preferential induction of apoptosis for human acute myelogenous leukemia stem cells. *PNAS*, 99(25):16220-16225. [PMID:12451177](#).
24. Goodrum, F.D., **Jordan, C.T.**, High, K., and Shenk, T (2002). Human cytomegalovirus gene expression during infection of primary hematopoietic progenitor cells: a model for latency. *PNAS*, 99(25):16255-16260. [PMID:12456880](#).
25. Topisirovic, I., Guzman, M.L., McConnell, M.J., Licht, J.D., Culjkovic, B., Neering, S.J., **Jordan, C.T.**, and Borden, K.L. (2003). Aberrant eukaryotic translation initiation factor 4E-dependent

- mRNA transport impedes hematopoietic differentiation and contributes to leukemogenesis. *MCB*, 23(24):8992-9002. [PMID:14645512](#).
26. Goodrum, F., **Jordan, C.T.**, Terhune, S.S., High, K., and Shenk T. (2004). Differential outcomes of human cytomegalovirus infection in primitive hematopoietic subpopulations. *Blood*, 104(3):687-95. [PMID:15090458](#).
  27. **Jordan, C.T.** and Guzman, M. L. (2004) Mechanisms controlling pathogenesis and survival of leukemic stem cells. *Oncogene*, 23(43):7178-87. [PMID:15378078](#).
  28. Topisirovic, I., Kentsis, A., Perez, J.M., Guzman, M.L., **Jordan, C.T.**, and Borden, K.L. (2005). Eukaryotic translation initiation factor 4E activity is modulated by HoxA9 at multiple levels. *MCB*, 25(3):1100-1112. [PMID:15657436](#).
  29. Guzman, M.L., Rossi, R.M., Karnischky, L., Li, X., Peterson, D., Howard, D.S., and **Jordan, C.T.** (2005). The sesquiterpene lactone parthenolide induces apoptosis of human acute myelogenous leukemia stem and progenitor cells. *Blood – Plenary Paper*, 105(11):4163-69. [PMID:15687234](#).
  30. Klebanov, L., **Jordan, C.**, and Yakovlev, A., (2006). A new type of stochastic dependence revealed in gene expression data. *Statistical Applications in Genetics and Molecular Biology*, 5(1): article 7. [PMID:16646871](#).
  31. Weber JM, Forsythe SR, Christianson CA, Frisch BJ, Gigliotti BJ, **Jordan CT**, Milner LA, Guzman ML, Calvi LM. (2006) Parathyroid hormone stimulates expression of the Notch ligand Jagged1 in osteoblastic cells. *Bone*, 39(3):485-493. [PMID:16647886](#).
  32. Bostrom MA, Boyanovsky BB, **Jordan CT**, Wadsworth MP, Taatjes DJ, de Beer FC, Webb NR (2007). Group V Secretory Phospholipase A2 Promotes Atherosclerosis. Evidence From Genetically Altered Mice. *Arterioscler Thromb Vasc Biol*. 2007 Jan 4. [PMID:17204667](#).
  33. Neering, SJ, Bushnell, T., Sozer, S., Ashton, J., Rossi, RM, Wang, PY, Bell, DR, Heinrich, D., Bottaro, A., and **Jordan, CT** (2007). Leukemia stem cells in a genetically defined murine model of blast crisis CML. *Blood*, 110(7):2578-85. [PMID:17601986](#).
  34. Guzman, ML, S, Li, S, Corbett, C, Rossi, RM, Bushnell T, Liesveld, JL, Hebert J, Young, F and **Jordan, CT** (2007). Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8). *Blood*, 110(13):4436-44. [PMID:17785584](#).
  35. Guzman, ML, Rossi, RM, Neelakantan, S, Li, S, Corbett, C, Hassane, DC, Becker, MW, Bennett, J, Sullivan, E, Lachowicz, JL, Sweeney, CJ, Matthews, W, Carroll, M, Crooks, PA, and **Jordan, CT** (2007). An orally bioavailable parthenolide analog selectively eradicates acute myelogenous leukemia stem and progenitor cells. *Blood*, 110(13):4427-35. [PMID:17804695](#).
  36. Kim SW, Oleksyn DW, Rossi RM, **Jordan CT**, Sanz I, Chen L, Zhao J (2008). Protein kinase C-associated kinase PKK is required for NF- $\kappa$ B signaling and survival in diffuse large B-cell lymphoma cells. *Blood*, 111(3):1644-53. [PMID:18025152](#).
  37. Hewamana S, Alghazal S, Lin TT, Clement M, Jenkins C, Guzman ML, **Jordan CT**, Neelakantan S, Crooks PA, Burnett AK, Pratt G, Fegan C, Rowntree C, Brennan P, Pepper C (2008). The NF-

- {kappa}B subunit, Rel A, is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. *Blood*, 111(9):4681-9. [PMID:18227347](#).
38. Mao G, Yua F, Absher K, Jennings CD, Howard DS, **Jordan CT**, and Gu L (2008) Preferential Loss of Mismatch Repair Function in Refractory and Relapsed Acute Myeloid Leukemia: potential contribution to AML Progression. *Cell Research*, 18(2):281-289. [PMID:18227862](#).
  39. Hassane, DC, Guzman, ML, Corbett, C, Li, X, Abboud, R, Young, F, Liesveld, JL, Carroll, M, and **Jordan, CT** (2008). Discovery of Agents that Eradicate Leukemia Stem Cells Using an In Silico Screen of Public Gene Expression Data. *Blood*, 111(12):5654-62. [PMID:18305216](#).
  40. Young, FM, Campbell, A, Emo, KL, Jansson, J, Wang, PY, **Jordan, CT**, and Mullen, CA (2008) High risk acute lymphoblastic leukemia cells with BCR-ABL and INK4A/ARF mutations retain susceptibility to alloreactive T cells. *Biology of Blood and Marrow Transplantation*, 14(6):622-30. [PMID:18489987](#).
  41. Mendler JH, Kelly J, Voci S, Marquis D, Rich L, Rossi RM, Bernstein SH, **Jordan CT**, Liesveld J, Fisher RI, and Friedberg JW (2008). Bortezomib and gemcitabine in relapsed or refractory Hodgkin's lymphoma. *Ann Oncol*. 19(10):1759-64. [PMID:18504251](#).
  42. Wang, PY, Young, F, Chen, CY, Stevens, BM, Neering, SJ, Rossi, RM, Bushnell T, Heinrich, D, Bottaro, A, and **Jordan, CT** (2008) The biological properties of leukemias arising from BCR/ABL-mediated transformation vary as a function of developmental origin and activity of the p19<sup>ARF</sup> gene. *Blood*, 112(10):4184-92. [PMID:18755985](#).
  43. Hewamana, S, Lin TT, Jenkins, C, Burnett, AK, **Jordan, CT**, Fegan, C, Brennan, P, Rowntree, C, and Pepper, C. (2008) The novel NF-kB inhibitor LC-1 is equipotent in poor prognostic subsets of CLL and shows strong synergy with fludarabine. *Clinical Cancer Research*. 14(24):8102-11. [PMID:19088025](#).
  44. Korver W, Zhao X, Singh S, Pardoux C, Zhao J, Guzman ML, Sen S, Yonkovich S, Liu S, Zhan X, Tomasevic N, Zhou C, Gros D, **Jordan CT**, Gotlib J, Hsi ED, Abo A. Monoclonal antibodies against IREM-1: potential for targeted therapy of AML. *Leukemia*. 2009 Sep;23(9):1587-97. [PMID:19440216](#).
  45. Neelakantan, S, Nasim, S, Guzman ML, **Jordan, CT**, and Crooks, PA. Aminoparthenolides as novel anti-leukemic agents: discovery of the NF-kB inhibitor, DMAPT (LC-1). *Bioorg Med Chem Lett*, 2009 Aug 1;19(15):4346-9. [PMID:19505822](#).
  46. Frisch BJ, Porter RL, Gigliotti BJ, Olm-Shipman AJ, Weber JM, O'Keefe RJ, **Jordan CT**, Calvi LM. In vivo prostaglandin E2 treatment alters the bone marrow microenvironment and preferentially expands short-term hematopoietic stem cells. *Blood*. 2009 Nov 5;114(19):4054-63. [PMID:19726721](#).
  47. Rosen, J.M., and **Jordan, C.T.** (2009) The increasing complexity of the cancer stem cell paradigm. *Science*, 2009 Jun 26;324(5935):1670-73. [PMID:19556499](#).
  48. Skalska J, Brookes PS, Nadtochiy SM, Hilchey SP, **Jordan CT**, Guzman ML, Maggirwar SB, Briehl MM, and Bernstein SH. Modulation of cell surface protein free thiols: a potential novel

- mechanism of action of the sesquiterpene lactone parthenolide. *PLoS One*, 2009 Dec 2;4(12):e8115. [PMID:19956548](#).
49. Ito T, Kwon HY, Zimdahl B, Congdon KL, Blum J, Lento WE, Zhao C, Lagoo A, Gerrard G, Foroni L, Goldman J, Goh H, Kim SH, Kim DW, Chuah C, Oehler VG, Radich JP, **Jordan CT**, and Reya T. Regulation of myeloid leukemia by the cell fate determinant Musashi. *Nature*, 2010 Aug 5;466(7307):765-8. [PMID:20639863](#).
50. Silvers,CR, Williams K, Salamone L, Huang J, **Jordan CT**, Zhou H, and Palapattu GS. A novel in vitro assay of tumor-initiating cells in xenograft prostate tumors. *Prostate*, 2010 Sept 15;70(13):1379-87. [PMID:20687210](#).
51. Dai Y, Guzman ML, Chen S, Wang L, Yeung SK, Pei XY, Dent P, **Jordan CT**, and Grant S. The NF(Nuclear Factor)-kB inhibitor parthenolide interacts with histone deacetylase inhibitors to induce MKK7/JNK1-dependent apoptosis in human acute myeloid leukemia cells. *British Journal of Hematology*, 2010 Oct; 15(1):70-83. [PMID:20701602](#).
52. Hassane DC, Sen S, Minhajuddin M, Rossi RM, Corbett CA, Balys M, Wei L, Crooks PA, Guzman ML, and **Jordan CT**. Chemical Genomic Screening Reveals Synergism between Parthenolide and Inhibitors of the PI-3 Kinase and mTOR Pathways. *Blood*, 2010 Dec 23;116(26):5983-90. [PMID:20889920](#).
53. Nasim S, Pei S, Hagen FK, **Jordan CT**, and Crooks PA. Melampomagnolide B: a new antileukemic sesquiterpene. *Bioorg and Med Chem*, 2011, Jan 6. [PMID:21273084](#).
54. Liesveld JL, Rosell KE, Bechelli J, Lu C, Messina P, Mulford D, Ifthikharuddin JJ, Jordan CT, and Phillips GL. Proteasome inhibition in myelodysplastic syndromes and acute myelogenous leukemia cell lines. *Cancer Invest*. 2011 Aug;29(7):439-50. [PMID:21740082](#).
55. Nasim S, Guzman, ML, **Jordan CT**, and Crooks PA. Discovery of 1,2,4-thiadiazolidine-3,5-dione analogs that exhibit unusual and selective rapid cell death kinetics against acute myelogenous leukemia cells in culture. *Bioorganic & Medicinal Chemistry Letters*, 2011 Aug 15;21(16):4879-83. [PMID:21757349](#).
56. Benito J, Shi Y, Szymanska B, Carol H, Boehm I, Lu H, Konoplev S, Fang W, Zweidler-McKay PA, Campana D, Borthakur G, Bueso-Ramos C, Shpall E, Thomas DA, **Jordan CT**, Kantarjian H, Wilson WR, Lock R, Andreeff M, and Konopleva M. Pronounced Hypoxia in Models of Murine and Human Leukemia: High Efficacy of Hypoxia-Activated Prodrug PR-104. *PLoS One*. 2011;6(8):e23108. [PMID:21853076](#).
57. Frisch, B.J., Ashton, J.M., Xing, L., Becker, M.W., **Jordan, CT**, and Calvi, L.M. (2011). Functional inhibition of osteoblastic cells in an in vivo mouse model of myeloid leukemia. *Blood*, 2012, 119(2):540-50. [PMID:21957195](#).
58. Zhao C, Xiu Y, Ashton J, Xing L, Morita Y, **Jordan CT**, Boyce BF. Non-Canonical NF-kB Signaling Regulates Hematopoietic Stem Cell Self-Renewal and Microenvironment Interactions. *Stem cells*. 2012;Epub 2012 Jan 30. [PMID:22290873](#).
59. Ashton, J.M., Balys, M., Neering, S.J., Hassane, D.C., Cowley, G., Root, D.E., Miller, P.G., Ebert, B.L., McMurray, H.R., Land, H., and **Jordan C.T**. Oncogene cooperativity analysis reveals a

- novel set of genes that regulate the in vivo growth and survival of leukemia stem cells. *Cell Stem Cell*. 2012 Sep 7;11(3):359-72. [PMID:22863534](#).
60. Sampson ER, McMurray HR, Hassance DC, Newman L, Salzman P, **Jordan CT**, and Land H. Gene signature critical to cancer phenotype as a paradigm for anticancer drug discovery. *Oncogene*. 2012 Sep 10. [PMID:22964631](#).
61. Lagadinou, ED. Sach, A, Callahan, K, Rossi, RM, Neering, S, Pei S, O'Dwyer, KM, Liesveld, JL, Becker, MW, Brookes, PS, and **Jordan CT**. Bcl-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. *Cell Stem Cell*, 2013 Mar 7;12(3):329-41. [PMID:23333149](#).
62. Nielsen TH, Johnson N, Garnier N, Kwan S, Yao L, Cocolakis E, Hebert J, Morgan RA, Paquet E, Callahan KP, **Jordan CT**, Assouline S, Miller WH, and Mann KK. Monitoring response and resistance to the novel arsenical darinaparsin in an AML patient. *Frontiers in Pharmacology of Cancer Drugs*, 2013;4:9. [PMID:23408639](#).
63. Sen S, Hassane DC, Corbett C, Becker MW, **Jordan CT**, Guzman ML. Novel mTOR inhibitory activity of ciclopirox enhances parthenolide antileukemia activity. *Exp Hematol*. 2013 May 6. [epub ahead of print]. [PMID:23660068](#).
64. Miller PG, Al-Shahrour F, Hartwell KA, Chu LP, Järås M, Puram RV, Puissant A, Callahan KP, Ashton J, McConkey ME, Poveromo LP, Cowley GS, Kharas MG, Labelle M, Shterental S, Fujisaki J, Silberstein L, Alexe G, Al-Hajj MA, Shelton CA, Armstrong SA, Root DE, Scadden DT, Hynes RO, Mukherjee S, Stegmaier K, **Jordan CT**, Ebert BL. In vivo RNAi screening identifies a leukemia-specific dependence on integrin beta 3 signaling. *Cancer Cell*, 2013 Jun 11 [epub ahead of print]. [PMID:23770013](#).
65. Pei S, Balys M, Callahan KP, Minhajuddin M, Ashton JM, Neering SJ, Lagadinou ED, Corbett C, Ye H, Becker MW, Liesveld JL, O'Dwyer KM, Li Z, Shi L, Greninger P, Settleman J, Benes C, Hagen F, Munger J, Crooks PA, and **Jordan CT**. Targeting aberrant glutathione metabolism to selectively eradicate human leukemia cells. *Journal of Biology Chemistry*. 2013 Nov 22;288(47):33542-58. [PMID:24089526](#).
66. Velu CS, Chaubey A, Phelan JD, Horman SR, Wunderlich M, Guzman ML, Jegga AG, Zeleznik-Le NJ, Chen J, Mulloy JC, Cancelas JA, **Jordan CT**, Aronow BJ, Marcucci G, Bhat B, Gebelein B, and Grimes HL. Therapeutic antagonists of microRNAs deplete leukemia-initiating cell activity. *Journal of Clinical Investigation*. 2013 Dec 16 (Epub ahead of print). <http://dy3uq8jh2v.search.serialssolutions.com/?sid=Entrez:PubMed&id=pmid:24334453>
67. Kolev JN, O'Dwyer KM, **Jordan CT**, and Fasan R. Discovery of potent parthenolide-based antileukemic agents enabled by late-stage P450-mediated C—H functionalization. *ACS Chemical Biology*. 2013 Nov 8 [Epub ahead of print] <http://dy3uq8jh2v.search.serialssolutions.com/?sid=Entrez:PubMed&id=pmid:24206617>
68. Liesveld JL, O'Dwyer K, Walker A, Becker MW, Ifthikharuddin JJ, Mulford D, Chen R, Bechelli J, Rosell K, Minhajuddin M, **Jordan CT**, and Phillips GL. A phase I study of decitabine and rapamycin in relapsed/refractory AML. *Leukemia Research*. 2013 Dec;37(12):1622-7. doi: 10.1016/j.leukres.2013.09.002. [PMID:24138944](#).

69. Howard DS, Liesveld J, Phillips GL, Hayslip J, Weiss H, **Jordan CT**, Guzman ML. A phase I study using bortezomib with weekly idarubicin for treatment of elderly patients with acute myeloid leukemia. *Leuk Res*. 2013 Sep 8. pii: S0145-2126(13)00320-2 [PMID:24075534](#).
70. Liu S, Miriyaia S, Keaton MA, **Jordan CT**, Wiedl C, St. Clair DK, Moscow JA. Metabolic effects of acute thiamine depletion are reversed by rapamycin in breast and leukemia cells. *PLoS One*. 2014 Jan 15;9(1):e85702  
<http://dy3uq8jh2v.search.serialssolutions.com/?sid=Entrez:PubMed&id=pmid:24454921>
71. Callahan KP, Minhajuddin M, Corbett C, Lagadinou ED, Rossi RM, Grose V, Balys MM, Pan L, Jacob S, Frontier A, Grever MR, Lucas DM, Kinghorn AD, Liesveld JL, Becker MW, and **Jordan CT**. Flavaglines target primitive leukemia cells and enhance anti-leukemia drug activity. *Leukemia*. 2014 Feb 28. doi: 10.1038/leu.2014.93. [Epub ahead of print] PMID: 24577530.  
<http://dy3uq8jh2v.search.serialssolutions.com/?sid=Entrez:PubMed&id=pmid:24577530>
72. Zahreddine HA, Culjkovic-Kraljacic B, Assouline S, Gendron P, Romeo AA, Morris SJ, Cormack G, Jaquith JB, Cerchiatti L, Cocolakis E, Amri A, Bergeron J, Leber B, Becker MW, Pei S, **Jordan CT**, Miller WH, and Borden KL. The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation. *Nature*, 2014 May 28 [epub ahead of print].  
<http://dy3uq8jh2v.search.serialssolutions.com/?sid=Entrez:PubMed&id=pmid:24870236>
73. Gandhi UH, Kaushal N, Hegde S, Finch ER, Kudva AK, Kennett MJ, **Jordan CT**, Paulson RF, Prabhu KS. Selenium suppresses leukemia through the action of endogenous eicosanoids. *Cancer Research*. 2014 May 28 [epub ahead of print]  
<http://dy3uq8jh2v.search.serialssolutions.com/?sid=Entrez:PubMed&id=pmid:24872387>
74. Kim SW, Schifano M, Oleksyn D, **Jordan CT**, Ryan D, Insel R, Zhao J, and Chen L. Protein kinase C-associated kinase regulates NF-kB activation through inducing IKK activation. *Int J Oncol*. 2014 Oct;45(4):1707-14. doi: 10.3892/ijo.2014.2578. Epub 2014 Aug 4. Pubmed [PMID:25096806](#).
75. Guzman ML, Yang N, Sharma KK, Balys M, Corbett CA, **Jordan CT**, Becker MW, Steidl U, Abdel-Wahab O, Levine RL, Marcucci G, Roboz GJ, Hassane DC. Selective activity of the histone deacetylase inhibitor AR-42 against leukemia stem cells: a novel potential strategy in acute myelogenous leukemia. *Mol Cancer Ther*. 2014 Aug;13(8):1979-90. doi: 10.1158/1535-7163.MCT-13-0963. Epub 2014 Jun 16. PubMed [PMID: 24934933](#); PubMed Central PMCID: PMC4383047.
76. Lee-Sherick AB, Zhang W, Menachof KK, Hill AA, Rinella S, Kirkpatrick G, Page LS, Stashko MA, **Jordan CT**, Wei Q, Liu J, Zhang D, DeRyckere D, Wang X, Frye S, Earp HS, Graham DK. Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia. *Oncotarget*. 2015 Mar 30;6(9):6722-36. PubMed [PMID: 25762638](#).
77. Alvarez-Calderon F, Gregory MA, Pham-Danis C, DeRyckere D, Stevens BM, Zaberezhnyy V, Hill AA, Gemta L, Kumar A, Kumar V, Wempe MF, Pollyea DA, **Jordan CT**, Serkova NJ, Graham DK, DeGregori J. Tyrosine kinase inhibition in leukemia induces an altered metabolic state sensitive to mitochondrial perturbations. *Clin Cancer Res*. 2015 Mar 15;21(6):1360-72. doi: 10.1158/1078-0432.CCR-14-2146. Epub 2014 Dec 29. PubMed [PMID: 25547679](#); PubMed Central PMCID: PMC4359967.



78. Koo GB, Morgan MJ, Lee DG, Kim WJ, Yoon JH, Koo JS, Kim SI, Kim SJ, Son MK, Hong SS, Levy JM, Pollyea DA, **Jordan CT**, Yan P, Frankhouser D, Nicolet D, Maharry K, Marcucci G, Choi KS, Cho H, Thorburn A, Kim YS. Methylation-dependent loss of RIP3 expression in cancer represses programmed necrosis in response to chemotherapeutics. *Cell Res*. 2015 May 8. doi: 10.1038/cr.2015.56. PubMed [PMID: 25952668](#).
79. Stevens B, Maxson J, Tyner J, Smith CA, Gutman JA, Robinson W, **Jordan CT**, Lee CK, Swissheim K, Tobin J, Wei Q, Schowinsky J, Rinella S, Lee HG, and Pollyea DA. Clonality of neutrophilia associated with plasma cell neoplasms: report of a SETBP1 mutation and analysis of a single institution series. *Leuk Lymphoma*. 2015 Sep 21:1-22. Pubmed [PMID: 26389776](#).
80. Janganani V, Ponder J, **Jordan CT**, Borrelli MJ, Penthala NR, Crooks PA. Dimers of Melampomagnolide B Exhibit Potent Anticancer Activity against Hematological and Solid Tumor Cells. *J Med Chem*. 2015 Nov 25;58(22):8896-906. doi:10.1021/acs.jmedchem.5b01187. Epub 2015 Nov 16. PubMed [PMID: 26540463](#).
81. Smith KS, Yadav VK, Pei S, Pollyea DA, **Jordan CT**, De S. SomVarIUS: Somatic variant identification from unpaired tissue samples. *Bioinformatics*. 2015 Nov 20. pii: btv685. [Epub ahead of print] PubMed [PMID: 26589277](#).
82. Riedel SS, Haladyna JN, Bezzant M, Stevens B, Pollyea DA, Sinha AU, Armstrong SA, Wei Q, Pollock RM, Daigle SR, **Jordan CT**, Ernst P, Neff T, Bernt KM. MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemia. *J Clin Invest*. 2016 Feb 29. pii: 80825. doi: 10.1172/JCI80825. [Epub ahead of print]. PubMed [PMID: 26927674](#)
83. Minson KA, Smith CC, DeRyckere D, Libbrecht C, Lee-Sherick AB, Huey MG, Lasater EA, Kirkpatrick GD, Stashko MA, Zhang W, **Jordan CT**, Kireev D, Wang X, Frye SV, Earp HS, Shah NP, Graham DK. The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. *JCI Insight*. 2016 Mar;1(3):e85630. [PubMed PMID: 27158668](#); PubMed Central PMCID: PMC4855528.
84. Khwaja A, Bjorkholm M, Gale RE, Levine RL, **Jordan CT**, Ehninger G, Bloomfield CD, Estey E, Burnett A, Cornelissen JJ, Scheinberg DA, Bouscary D, Linch DC. Acute myeloid leukaemia. *Nat Rev Dis Primers*. 2016 Mar 10;2:16010. doi: 10.1038/nrdp.2016.10. PubMed [PMID: 27159408](#).
85. Ye H, Adane B, Khan N, Sullivan T, Minhajuddin M, Gasparetto M, Stevens B, Pei S, Balys M, Ashton JM, Klemm DJ, Woolthuis CM, Stranahan AW, Park CY, **Jordan CT**. Leukemic Stem Cells Evade Chemotherapy by Metabolic Adaptation to an Adipose Tissue Niche. *Cell Stem Cell*. 2016 Jul 7;19(1):23-37. doi: 10.1016/j.stem.2016.06.001. Epub 2016 Jun 30. PubMed [PMID: 27374788](#); PubMed Central PMCID: PMC4938766.
86. Tyagi V, Alwaseem H, O'Dwyer KM, Ponder J, Li QY, **Jordan CT**, Fasan R. Chemoenzymatic synthesis and antileukemic activity of novel C9- and C14-functionalized parthenolide analogs. *Bioorg Med Chem*. 2016 Jun 16. pii:S0968-0896(16)30451-5. doi: 10.1016/j.bmc.2016.06.028. [Epub ahead of print] PubMed [PMID: 27396927](#).
87. Ho TC, LaMere M, Stevens BM, Ashton JM, Myers JR, O'Dwyer KM, Liesveld JL, Mendler JH, Guzman M, Morrissette JD, Zhao J, Wang ES, Wetzler M, **Jordan CT**, Becker MW. Evolution of acute myelogenous leukemia stem cell properties following treatment and progression. *Blood*.

2016 Jul 15. pii: blood-2016-02-695312. [Epub ahead of print] PubMed [PMID: 27421961](#).  
**\*Selected as a 2016 top 10 paper of the year for Blood**

88. Pei S, Minhajuddin M, D'Alessandro A, Nemkov T, Stevens BM, Adane B, Khan N, Hagen FK, Yadav VK, De S, Ashton JM, Hansen KC, Gutman JA, Pollyea DA, Crooks PA, Smith C, **Jordan CT**. Rational Design of a Parthenolide-based Drug Regimen that Selectively Eradicates Acute Myelogenous Leukemia Stem Cells. *J Biol Chem*. 2016 Aug 29. pii: jbc.M116.750653. [Epub ahead of print] PubMed [PMID: 27573247](#).
89. Li B, Zhao W, Zhang X, Wang J, Luo X, Baker SD, **Jordan CT**, Dong Y. Design, synthesis and evaluation of anti-CD123 antibody drug conjugates. *Bioorg Med Chem*. 2016 Nov 15;24(22):5855-5860. doi: 10.1016/j.bmc.2016.09.043. Epub 2016 Sep 17. PubMed [PMID: 27687970](#); PubMed Central PMCID: PMC5318162.
90. Gregory MA, D'Alessandro A, Alvarez-Calderon F, Kim J, Nemkov T, Adane B, Rozhok AI, Kumar A, Kumar V, Pollyea DA, Wempe MF, **Jordan CT**, Serkova NJ, Tan AC, Hansen KC, DeGregori J. ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia. *Proc Natl Acad Sci U S A*. 2016 Oct 25;113(43):E6669-E6678. Epub 2016 Oct 10. PubMed [PMID: 27791036](#); PubMed Central PMCID: PMC5086999.
91. Albayati ZA, Janganani V, Chen Z, Ponder J, Breen PJ, **Jordan CT**, Crooks PA. Identification of a melampomagnolide B analog as a potential lead molecule for treatment of acute myelogenous leukemia. *Bioorg Med Chem*. 2017 Feb 1;25(3):1235-1241. doi: 10.1016/j.bmc.2016.12.036. Epub 2016 Dec 26. PubMed [PMID: 28049618](#); PubMed Central PMCID: PMC5291787.
92. Gasparetto M, Pei S, Minhajuddin M, Khan N, Pollyea DA, Myers JR, Ashton JM, Becker MW, Vasiliou V, Humphries KR, **Jordan CT**, Smith CA. Targeted therapy for a subset of acute myeloid leukemias that lack expression of aldehyde dehydrogenase 1A1. *Haematologica*. 2017 Mar 9. pii: haematol.2016.159053. doi: 10.3324/haematol.2016.159053. [Epub ahead of print] PubMed [PMID: 28280079](#).
93. Janganani V, Ponder J, Thakkar S, **Jordan CT**, Crooks PA. Succinamide derivatives of melampomagnolide B and their anti-cancer activities. *Bioorganic & medicinal chemistry*. 2017; 25(14):3694-3705. NIHMSID: NIHMS878841 PubMed [journal] [PMID: 28545815](#), PMCID: PMC5531864
94. Bommagani S, Ponder J, Penthala NR, Janganani V, **Jordan CT**, Borrelli MJ, Crooks PA. Indole carboxylic acid esters of melampomagnolide B are potent anticancer agents against both hematological and solid tumor cells. *European journal of medicinal chemistry*. 2017; 136:393-405. NIHMSID: NIHMS877447 PubMed [journal] [PMID: 28525840](#), PMCID: PMC5531865
95. Garcia TB, Snedeker JC, Baturin D, Gardner L, Fosmire SP, Zhou C, **Jordan CT**, Venkataraman S, Vibhakar R, Porter CC. A Small-Molecule Inhibitor of WEE1, AZD1775, Synergizes with Olaparib by Impairing Homologous Recombination and Enhancing DNA Damage and Apoptosis in Acute Leukemia. *Molecular cancer therapeutics*. 2017; 16(10):2058-2068. NIHMSID: NIHMS887909 PubMed [journal] [PMID: 28655785](#), PMCID: PMC5628125.
96. Pei S, Minhajuddin M, Adane B, Khan N, Stevens BM, Mack SC, Lai S, Rich JN, Inguva A, Shannon KM, Kim H, Tan AC, Myers JR, Ashton JM, Neff T, Pollyea DA, Smith CA, **Jordan CT**. AMPK/FIS1-Mediated Mitophagy Is Required for Self-Renewal of Human AML Stem Cells. *Cell*

- Stem Cell.** 2018 Jun 6. pii: S1934-5909(18)30239-X. doi: 10.1016/j.stem.2018.05.021. [Epub ahead of print] PubMed [PMID: 29910151](#).
97. Stevens BM, Khan N, D'Alessandro A, Nemkov T, Winters A, Jones CL, Zhang W, Pollyea DA, **Jordan CT**. Characterization and targeting of malignant stem cells in patients with advanced myelodysplastic syndromes. *Nat Commun.* 2018 Sep 12;9(1):3694. doi: 10.1038/s41467-018-05984-x. PubMed [PMID: 30209285](#); PubMed Central PMCID: PMC6135858.
98. Ye H, Adane B, Khan N, Alexeev E, Nusbacher N, Minhajuddin M, Stevens BM, Winters AC, Lin X, Ashton JM, Purev E, Xing L, Pollyea DA, Lozupone CA, Serkova NJ, Colgan SP, **Jordan CT**. Subversion of Systemic Glucose Metabolism as a Mechanism to Support the Growth of Leukemia Cells. *Cancer Cell.* 2018 Oct 8;34(4):659-673.e6. doi: 10.1016/j.ccell.2018.08.016. Epub 2018 Sep 27. PubMed [PMID: 30270124](#); PubMed Central PMCID: PMC6177322. **\*Selected to the "Best of Cancer Cell 2018" list.**
99. Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, Long N, Schultz AR, Traer E, Abel M, Agarwal A, Blucher A, Borate U, Bryant J, Burke R, Carlos A, Carpenter R, Carroll J, Chang BH, Coblenz C, d'Almeida A, Cook R, Danilov A, Dao KT, Degnin M, Devine D, Dibb J, Edwards DK 5th, Eide CA, English I, Glover J, Henson R, Ho H, Jemal A, Johnson K, Johnson R, Junio B, Kaempf A, Leonard J, Lin C, Liu SQ, Lo P, Loriaux MM, Luty S, Macey T, MacManiman J, Martinez J, Mori M, Nelson D, Nichols C, Peters J, Ramsdill J, Rofelty A, Schuff R, Searles R, Segerdell E, Smith RL, Spurgeon SE, Sweeney T, Thapa A, Visser C, Wagner J, Watanabe-Smith K, Werth K, Wolf J, White L, Yates A, Zhang H, Cogle CR, Collins RH, Connolly DC, Deininger MW, Drusbosky L, Hourigan CS, **Jordan CT**, Kropf P, Lin TL, Martinez ME, Medeiros BC, Pallapati RR, Pollyea DA, Swords RT, Watts JM, Weir SJ, Wiest DL, Winters RM, McWeeney SK, Druker BJ. Functional genomic landscape of acute myeloid leukaemia. *Nature.* 2018 Oct;562(7728):526-531. doi: 10.1038/s41586-018-0623-z. Epub 2018 Oct 17. PubMed [PMID: 30333627](#); PubMed Central PMCID: PMC6280667.
100. Lee-Sherick AB, Jacobsen KM, Henry CJ, Huey MG, Parker RE, Page LS, Hill AA, Wang X, Frye SV, Earp HS, **Jordan CT**, DeRyckere D, Graham DK. MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity. *JCI Insight.* 2018 Nov 2;3(21). pii: 97941. doi: 10.1172/jci.insight.97941. [Epub ahead of print] PubMed [PMID: 30385715](#); PubMed Central PMCID: PMC6238750.
101. Jones CL, Stevens BM, D'Alessandro A, Reisz JA, Culp-Hill R, Nemkov T, Pei S, Khan N, Adane B, Ye H, Krug A, Reinhold D, Smith C, DeGregori J, Pollyea DA, **Jordan CT**. Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells. *Cancer Cell.* 2018 Nov 12;34(5):724-740.e4. doi: 10.1016/j.ccell.2018.10.005. Erratum in: *Cancer Cell.* 2019 Feb 11;35(2):333-335. PubMed [PMID: 30423294](#); PubMed Central PMCID: PMC6280965.
102. Pollyea DA, Stevens BM, Jones CL, Winters A, Pei S, Minhajuddin M, D'Alessandro A, Culp-Hill R, Riemondy KA, Gillen AE, Hesselberth JR, Abbott D, Schatz D, Gutman JA, Purev E, Smith C, **Jordan CT**. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. *Nat Med.* 2018 Dec;24(12):1859-1866. doi:10.1038/s41591-018-0233-1. Epub 2018 Nov 12. PubMed [PMID: 30420752](#).
103. Pollyea DA, Harris C, Rabe JL, Hedin BR, De Arras L, Katz S, Wheeler E, Bejar R, Walter MJ, **Jordan CT**, Pietras EM, Alper S. Myelodysplastic syndrome-associated spliceosome gene mutations enhance innate immune signaling. *Haematologica.* 2019 Mar 7. pii:

haematol.2018.214155. doi: 10.3324/haematol.2018.214155. [Epub ahead of print] PubMed PMID: [30846499](#).

104. Gregory MA, Nemkov T, Park HJ, Zaberezhnyy V, Gehrke S, Adane B, **Jordan CT**, Hansen KC, D'Alessandro A, DeGregori J. Targeting glutamine metabolism and redox state for leukemia therapy. *Clin Cancer Res*. 2019 Apr 2. pii: clincanres.3223.2018. doi: 10.1158/1078-0432.CCR-18-3223. [Epub ahead of print] PubMed PMID: 30940653.
105. Adane B, Ye H, Khan N, Pei S, Minhajuddin M, Stevens BM, Jones CL, D'Alessandro A, Reisz JA, Zaberezhnyy V, Gasparetto M, Ho TC, Kelly KK, Myers JR, Ashton JM, Siegenthaler J, Kume T, Campbell EL, Pollyea DA, Becker MW, **Jordan CT**. The Hematopoietic Oxidase NOX2 Regulates Self-Renewal of Leukemic Stem Cells. *Cell Rep*. 2019 Apr 2;27(1):238-254.e6. doi: 10.1016/j.celrep.2019.03.009. PubMed PMID: 30943405.
106. Hernandez G, Mills TS, Rabe JL, Chavez JS, Kuldaneck S, Kirkpatrick G, Noetzli L, Jubair WK, Zanche M, Meyers JR, Stevens BM, Fleenor CJ, Adane B, Dinarello CA, Ashton J, **Jordan CT**, Di Paola J, Hagman JR, Holers VM, Kuhn KA, Pietras EM. Pro-inflammatory cytokine blockade attenuates myeloid expansion in a murine model of rheumatoid arthritis. *Haematologica*. 2019 May 17. pii: haematol.2018.197210. doi: 10.3324/haematol.2018.197210. [Epub ahead of print] PubMed PMID: 31101752.
107. Stevens B, Winters A, Gutman JA, Fullerton A, Hemenway G, Schatz D, Miltgen N, Wei Q, Abbasi T, Vali S, Singh NK, Drusbosky L, Cogle CR, Hammes A, Abbott D, **Jordan CT**, Smith C, Pollyea DA. Sequential azacitidine and lenalidomide for patients with relapsed and refractory acute myeloid leukemia: Clinical results and predictive modeling using computational analysis. *Leuk Res*. 2019 Jun;81:43-49. doi: 10.1016/j.leukres.2019.04.005. Epub 2019 Apr 13. PubMed PMID: 31009835.
108. Stevens BM, Zhang W, Pollyea DA, Winters A, Gutman J, Smith C, Budde E, Forman SJ, **Jordan CT**, Purev E. CD123 CAR T cells for the treatment of myelodysplastic syndrome. *Exp Hematol*. 2019 Jun;74:52-63.e3. doi: 10.1016/j.exphem.2019.05.002. Epub 2019 May 25. PubMed PMID: 31136781.
109. Jones CL, Stevens BM, D'Alessandro A, Culp-Hill R, Reisz JA, Pei S, Gustafson A, Khan N, DeGregori J, Pollyea DA, **Jordan CT**. Cysteine depletion targets leukemia stem cells through inhibition of electron transport complex II. *Blood*. 2019 Jul 25;134(4):389-394. doi: 10.1182/blood.2019898114. Epub 2019 May 17. PubMed PMID: 31101624.
110. Winters AC, Gutman JA, Purev E, Nakic M, Tobin J, Chase S, Kaiser J, Lyle L, Boggs C, Halsema K, Schowinsky JT, Rosser J, Ewalt MD, Siegele B, Rana V, Schuster S, Abbott D, Stevens BM, **Jordan CT**, Smith C, Pollyea DA. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. *Blood Adv*. 2019 Oct 22;3(20):2911-2919. doi: 10.1182/bloodadvances.2019000243. PubMed PMID: 31648312; PubMed Central PMCID: PMC6849960.
111. Pei S, Pollyea DA, Gustafson A, Stevens BM, Minhajuddin M, Fu R, Riemondy KA, Gillen AE, Sheridan RM, Kim J, Costello JC, Amaya ML, Inguva A, Winters A, Ye H, Krug A, Jones CL, Adane B, Khan N, Ponder J, Schowinsky J, Abbott D, Hammes A, Myers JR, Ashton JM, Nemkov T, D'Alessandro A, Gutman JA, Fesik SW, Ramsey HE, Savona MR, Smith CA, **Jordan CT**. Monocytic subclones confer resistance to venetoclax-based therapy in acute myeloid

- leukemia patients. **Cancer Discovery**. 2020 Apr;10(4):536-551. doi: 10.1158/2159-8290.CD-19-0710. Epub 2020 Jan 23. PMID: 31974170
112. Walker ZJ, VanWyngarden MJ, Stevens BM, Abbott D, Hammes A, Langouët-Astrie C, Smith CA, Palmer BE, Forsberg PA, Mark TM, **Jordan CT**, Sherbenou DW. Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression. **Blood Adv**. 2020 Apr 28;4(8):1628-1639. doi: 10.1182/bloodadvances.2019000122. PMID: 32311014
113. Matheson CJ, Casalvieri KA, Backos DS, Minhajuddin M, **Jordan CT**, Reigan P. Substituted oxindol-3-ylidenes as AMP-activated protein kinase (AMPK) inhibitors. **Eur J Med Chem**. 2020 Jul 1;197:112316. doi: 10.1016/j.ejmech.2020.112316. Epub 2020 Apr 16. PMID: 32334266
114. Jones CL, Stevens BM, Pollyea DA, Culp-Hill R, Reisz JA, Nemkov T, Gehrke S, Gamboni F, Krug A, Winters A, Pei S, Gustafson A, Ye H, Inguva A, Amaya M, Minhajuddin M, Abbott D, Becker MW, DeGregori J, Smith C, D'Alessandro A, **Jordan CT**. Nicotinamide metabolism mediates resistance to venetoclax in relapsed acute myeloid leukemia stem cells. **Cell Stem Cell**. 2020 Nov 5;27(5):748-764.e4. doi: 10.1016/j.stem.2020.07.021. Epub 2020 Aug 20. PMID: 32822582
115. Ye H, Minhajuddin M, Krug A, Pei S, Chou C-H, Culp-Hill R, Ponder J, De Bloois E, Schniedewind B, Amaya ML, Inguva A, Stevens BM, Pollyea DA, Christians U, Grimes HL, Lozupone CA, D'Alessandro A, **Jordan CT**. The Hepatic Microenvironment Uniquely Protects Leukemia Cells Through Induction of Growth and Survival Pathways Mediated by LIPG. **Cancer Discovery**. 2020 Oct 7:CD-20-0318. doi: 10.1158/2159-8290.CD-20-0318. Online ahead of print.
116. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells. Stevens BM, Jones CL, Pollyea DA, Culp-Hill R, D'Alessandro A, Winters A, Krug A, Abbott D, Goosman M, Pei S, Ye H, Gillen AE, Becker MW, Savona MR, Smith C, **Jordan CT**. **Nat Cancer**. 2020 Dec;1(12):1176-1187. doi: 10.1038/s43018-020-00126-z. Epub 2020 Oct 26. PMID: 33884374
117. Exploiting Protein Translation Dependence in Multiple Myeloma with Omacetaxine-based Therapy. Walker ZJ, Idler B, Davis L, Stevens BM, VanWyngarden M, Ohlstrom D, Bearrows SC, Hammes A, Smith CA, **Jordan CT**, Mark TM, Forsberg PA, Sherbenou DW. **Clin Cancer Res**. 2020 Oct 27:clincanres.2246.2020. doi: 10.1158/1078-0432.CCR-20-2246. Online ahead of print. PMID: 33109736
118. MDS-associated SF3B1 mutations enhance proinflammatory gene expression in patient blast cells. Pollyea DA, Kim HM, Stevens BM, Lee FF, Harris C, Hedin BR, Knapp JR, O'Connor BP, **Jordan CT**, Pietras EM, Tan AC, Alper S. **J Leukoc Biol**. 2020 Nov 6. doi: 10.1002/JLB.6AB0520-318RR. Online ahead of print. PMID: 33155727
119. MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity. Lee-Sherick AB, Jacobsen KM, Henry CJ, Huey MG, Parker RE, Page LS, Hill AA, Wang X, Frye SV, Earp HS, **Jordan CT**, DeRyckere D, Graham DK. **JCI Insight**. 2020 Dec 3;5(23):e145847. doi: 10.1172/jci.insight.145847. PMID: 33268596

120. The propriety of upgrading responses to venetoclax + azacitidine in newly diagnosed patients with acute myeloid leukemia. Abbott D, Cherry E, Amaya M, McMahon C, Schwartz M, Winters A, Schowinsky J, **Jordan CT**, Smith C, Gutman JA, Pollyea DA. *Leuk Lymphoma*. 2020 Dec 30;1-9. doi: 10.1080/10428194.2020.1864358. Online ahead of print. PMID: 33375853
121. Enriching for human acute myeloid leukemia stem cells using reactive oxygen species-based cell sorting. Stevens BM, O'Brien C, **Jordan CT**, Jones CL. *STAR Protoc*. 2020 Dec 30;2(1):100248. doi: 10.1016/j.xpro.2020.100248. **eCollection** 2021 Mar 19. PMID: 33437968
122. Comprehensive Structure-Activity Profiling of Micheliolide and its Targeted Proteome in Leukemia Cells via Probe-Guided Late-Stage C-H Functionalization. Alwaseem H, Giovani S, Crotti M, Welle K, **Jordan CT**, Ghaemmaghami S, Fasan R. *ACS Cent Sci*. 2021 May 26;7(5):841-857. doi: 10.1021/acscentsci.0c01624. Epub 2021 Apr 28. PMID: 34079900
123. PU.1 enforces quiescence and limits hematopoietic stem cell expansion during inflammatory stress. Chavez JS, Rabe JL, Loeffler D, Higa KC, Hernandez G, Mills TS, Ahmed N, Gessner RL, Ke Z, Idler BM, Niño KE, Kim H, Myers JR, Stevens BM, Davizon-Castillo P, **Jordan CT**, Nakajima H, Ashton J, Welner RS, Schroeder T, DeGregori J, Pietras EM. *J Exp Med*. 2021 Jun 7;218(6):e20201169. doi: 10.1084/jem.20201169. PMID: 33857288
124. Antitumor properties of novel sesquiterpene lactone analogs as NFκB inhibitors that bind to the IKKβ ubiquitin-like domain (ULD). Penthala NR, Balasubramaniam M, Dachavaram SS, Morris EJ, Bhat-Nakshatri P, Ponder J, **Jordan CT**, Nakshatri H, Crooks PA. *Eur J Med Chem*. 2021 Nov 15;224:113675. doi: 10.1016/j.ejmech.2021.113675. Epub 2021 Jun 30. PMID: 34229108
125. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Cherry EM, Abbott D, Amaya M, McMahon C, Schwartz M, Rosser J, Sato A, Schowinsky J, Inguva A, Minhajuddin M, Pei S, Stevens B, Winters A, **Jordan CT**, Smith C, Gutman JA, Pollyea DA. *Blood Adv*. 2021 Dec 28;5(24):5565-5573. doi: 10.1182/bloodadvances.2021005538. PMID: 34610123
126. Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60. Pollyea DA, Winters A, McMahon C, Schwartz M, **Jordan CT**, Rabinovitch R, Abbott D, Smith CA, Gutman JA. *Bone Marrow Transplant*. 2022 Feb;57(2):160-166. doi: 10.1038/s41409-021-01476-7. Epub 2021 Oct 13. PMID: 34645926
127. The STAT3-MYC axis promotes survival of leukemia stem cells by regulating SLC1A5 and oxidative phosphorylation. Amaya ML, Inguva A, Pei S, Jones C, Krug A, Ye H, Minhajuddin M, Winters A, Furtek SL, Gamboni F, Stevens B, D'Alessandro A, Pollyea DA, Reigan P, **Jordan CT**. *Blood*. 2022 Jan 27;139(4):584-596. doi: 10.1182/blood.2021013201. PMID: 34525179
128. Bottomly D, Long N, Schultz AR, Kurtz SE, Tognon CE, Johnson K, Abel M, Agarwal A, Avaylon S, Benton E, Blucher A, Borate U, Braun TP, Brown J, Bryant J, Burke R, Carlos A, Chang BH, Cho HJ, Christy S, Coblenz C, Cohen AM, d'Almeida A, Cook R, Danilov A, Dao KT, Degrin M, Dibb J, Eide CA, English I, Hagler S, Harrelson H, Henson R, Ho H, Joshi SK, Junio B, Kaempf A, Kosaka Y, Laderas T, Lawhead M, Lee H, Leonard JT, Lin C, Lind EF, Liu SQ, Lo P, Loriaux MM, Luty S, Maxson JE, Macey T, Martinez J, Minnier J, Montebianco A, Mori M, Morrow Q, Nelson D, Ramsdill J, Rofelty A, Rogers A, Romine KA, Ryabinin P, Saultz JN, Sampson DA, Savage SL, Schuff R, Searles R, Smith RL, Spurgeon SE, Sweeney T, Swords RT, Thapa A,

- Thiel-Klare K, Traer E, Wagner J, Wilmot B, Wolf J, Wu G, Yates A, Zhang H, Cogle CR, Collins RH, Deininger MW, Hourigan CS, **Jordan CT**, Lin TL, Martinez ME, Pallapati RR, Pollyea DA, Pomicter AD, Watts JM, Weir SJ, Druker BJ, McWeeney SK, Tyner JW. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. **Cancer Cell**. 2022 Aug 8;40(8):850-864.e9. doi: 10.1016/j.ccell.2022.07.002. Epub 2022 Jul 21. PMID: 35868306; PMCID: PMC9378589.
129. Park HJ, Gregory MA, Zaberezhnyy V, Goodspeed A, **Jordan CT**, Kieft JS, DeGregori J. Therapeutic resistance in acute myeloid leukemia cells is mediated by a novel ATM/mTOR pathway regulating oxidative phosphorylation. **Elife**. 2022 Oct 19;11:e79940. doi: 10.7554/eLife.79940. PMID: 36259537; PMCID: PMC9645811.
130. Culp-Hill R, Stevens BM, Jones CL, Pei S, Dzieciatkowska M, Minhajuddin M, **Jordan CT**, D'Alessandro A. Therapy-Resistant Acute Myeloid Leukemia Stem Cells Are Resensitized to Venetoclax + Azacitidine by Targeting Fatty Acid Desaturases 1 and 2. **Metabolites**. 2023 Mar 24;13(4):467. doi: 10.3390/metabo13040467. PMID: 37110126; PMCID: PMC10142983.
131. Pei S, Shelton IT, Gillen AE, Stevens BM, Gasparetto M, Wang Y, Liu L, Liu J, Brunetti TM, Engel K, Staggs S, Showers W, Sheth AI, Amaya ML, Minhajuddin M, Winters A, Patel SB, Tolison H, Krug AE, Young TN, Schowinsky J, McMahan CM, Smith CA, Pollyea DA, **Jordan CT**. A Novel Type of Monocytic Leukemia Stem Cell Revealed by the Clinical Use of Venetoclax-Based Therapy. **Cancer Discov**. 2023 Sep 6;13(9):2032-2049. doi: 10.1158/2159-8290.CD-22-1297. PMID: 37358260; PMCID: PMC10527971.
132. Gutman JA, Winters A, Kent A, Amaya M, McMahan C, Smith C, **Jordan CT**, Stevens B, Minhajuddin M, Pei S, Schowinsky J, Tobin J, O'Brien K, Falco A, Taylor E, Brecl C, Zhou K, Ho P, Sohalski C, Dell-Martin J, Ondracek O, Abbott D, Pollyea DA. Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia. **Haematologica**. 2023 Oct 1;108(10):2616-2625. doi: 10.3324/haematol.2023.282681. PMID: 37051756; PMCID: PMC10542846.
133. Schlein LJ, Brill SA, Brady RV, Farrell KB, Rose BJ, Meuten TK, **Jordan CT**, Thamm DH. Parthenolide As a Therapeutic for Disseminated Canine Neoplasms. **J Pharmacol Exp Ther**. 2024 Feb 15;388(3):774-787. doi: 10.1124/jpet.123.001851. PMID: 38135509; PMCID: PMC10877710.
134. Zhang X, Song B, Carlino MJ, Li G, Ferchen K, Chen M, Thompson EN, Kain BN, Schnell D, Thakkar K, Kouril M, Jin K, Hay SB, Sen S, Bernardicius D, Ma S, Bennett SN, Croteau J, Salvatori O, Lye MH, Gillen AE, **Jordan CT**, Singh H, Krause DS, Salomonis N, Grimes HL. An immunophenotype-coupled transcriptomic atlas of human hematopoietic progenitors. **Nat Immunol**. 2024 Apr;25(4):703-715. doi: 10.1038/s41590-024-01782-4. Epub 2024 Mar 21. PMID: 38514887; PMCID: PMC11003869.
135. Davis LN, Walker ZJ, Reiman LT, Parzych SE, Stevens BM, **Jordan CT**, Forsberg PA, Sherbenou DW. MYC Inhibition Potentiates CD8+ T Cells Against Multiple Myeloma and Overcomes Immunomodulatory Drug Resistance. **Clin Cancer Res**. 2024 May 9. doi: 10.1158/1078-0432.CCR-24-0256. Epub ahead of print. PMID: 38723281.
136. Winters AC, Minhajuddin M, Stevens BM, Major A, Bosma G, Abbott D, Miltgen N, Yuan J, Treece AL, Siegele BJ, Ewalt MD, Gutman JA, **Jordan CT**, Pollyea DA. Multi-gene measurable

residual disease assessed by digital polymerase chain reaction has clinical and biological utility in acute myeloid leukemia patients receiving venetoclax/azacitidine. **Haematologica**. 2024 Jun 1;109(6):1766-1778. doi: 10.3324/haematol.2023.283790. PMID: 38105738; PMCID: PMC11141685

137. Sahasrabudhe DM, Liesveld JL, Minhajuddin M, Singh NA, Nath S, Kumar VM, Balys M, Evans AG, Azadniv M, Hansen JN, Becker MW, Sharon A, Thomas VK, Moore RG, Khera MK, **Jordan CT**, Singh RK. In silico predicted compound targeting the IQGAP1-GRD domain selectively inhibits growth of human acute myeloid leukemia. **Sci Rep**. 2024 Jun 4;14(1):12868. doi: 10.1038/s41598-024-63392-2. PMID: 38834690; PMCID: PMC11150481.
138. Inguva-Sheth A, Althoff MJ, Tolison H, Engel K, Amaya ML, Krug A, Young A, Minhajuddin M, Pei S, Patel SB, Winters A, Miller R, Shelton I, St-Germain J, Ling T, Jones C, Raught B, Gillen A, Ransom M, Staggs S, Smith CA, Pollyea DA, Stevens BM, and **Jordan CT**. Targeting Acute Myeloid Leukemia Stem Cells Through Perturbation of Mitochondrial Calcium. **Cancer Discov**. 2024 May 24. doi: 10.1158/2159-8290.CD-23-1145. PMID: 38787341.
139. Minhajuddin M, Winters A, Ye H, Pei S, Stevens B, Gillen A, Engel K, Gipson S, Ransom M, Amaya M, Inguva A, Gasparetto M, Althoff MJ, Miller R, Shelton I, Tolison H, Krug A, Culp-Hill R, D'Alessandro A, Sherbenou DW, Pollyea DA, Smith C, **Jordan CT**. Lysosomal acid lipase A modulates leukemia stem cell response to venetoclax/tyrosine kinase inhibitor combination therapy in blast phase chronic myeloid leukemia. **Haematologica**. 2024 Jun 27. doi:10.3324/haematol.2023.284716. PMID: 38934082

## **Books**

1. Hematopoietic Stem Cell Protocols (2002), 1<sup>st</sup> Edition, by Christopher Klug and **Craig T. Jordan**, Methods in Molecular Medicine series, Humana Press, Totowa, New Jersey.

## **Invited Reviews, Editorials, Book Chapters**

1. **Jordan, C.T.**, and Van Zant, G. (1995) The Biology of Stem Cells. The Biomedical Engineering Handbook, CRC Press Inc.
2. **Jordan C.T.** and Van Zant, G. (1998). Recent progress in identifying genes regulating stem cell function and fate. *Current Opin. Cell Biol.*, 10:716-720. [PMID:9914177](#)
3. **Jordan C.T.**, Howard, D.S., Zhao, S.F., Yannelli, J.R., and Grimes, B. (1998). Transduction of primitive hematopoietic cells with adenovirus-polycation gene transfer vehicles: New strategies for management of hematologic disease. In Autologous Blood and Marrow Transplantation, Proceedings of the Ninth International Symposium, Carden Jennings Publishing.
4. Evans, M.E., **Jordan, C.T.**, et. al. (2000) Clinical infection control in gene therapy: A multidisciplinary conference. *Infect Control Hosp Epidemiol*, 21(10): 659-673. [PMID:11083185](#)
5. Lemischka, I.R., and **Jordan, C.T.** (2001) The return of clonal marking sheds new light on human hematopoietic stem cells. *Nature Immunology*, invited review, 2(1): 11-12. [PMID:11135569](#)



6. **Jordan, C.T.** and Nolta, J.A. (2001) Spotlight on hematopoietic stem cells: Looking beyond dogma. *Leukemia*, 15(11):1677-1680. [PMID:11681405](#)
7. Srour, E.F., and **Jordan, C.T.** (2002) Isolation of viable cells based on their position in cell cycle. In *Hematopoietic Stem Cell Protocols*, Humana Press, Totowa, New Jersey. [PMID:21437802](#)
8. **Jordan, C.T.** (2002) Unique molecular and cellular features of acute myelogenous leukemia stem cells. *Leukemia*, 16(4):559-562. [PMID:11960332](#)
9. Guzman, M.L., and **Jordan, C.T.** (2004) Considerations for targeting malignant stem cells in leukemia. *Cancer Control*, 11(2):97-104. [PMID:15024346](#)
10. Liesveld, J.L., **Jordan, C.T.**, and Phillips, G.L. (2004) The hematopoietic stem cell in myelodysplasia. *Stem Cells*, 22(4): 590-599. [PMID:15277704](#)
11. **Jordan, C. T.** (2004) A new approach to treatment of acute myelogenous leukemia using targeted therapy in combination with standard chemotherapy. *Leukemia Research*, 28(11): 1121-2. [PMID:15380333](#)
12. **Jordan, C.T.** (2004) Cancer stem cell biology: from leukemia to solid tumors. *Current Opinion in Cell Biology*, 16:708-712. [PMID:15530785](#)
13. Gilliland, D.G., **Jordan, C.T.**, and Felix, C.A. (2004) The molecular basis of leukemia. *Hematology (Am Soc Hematol Educ Program)*. p80-97. [PMID:15561678](#)
14. Guzman, M.L. and **Jordan, C.T.** (2005) Feverfew: weeding out the root of leukaemia. *Expert Opinion Biological Therapy*, 5(9):117-1152. [PMID:16120045](#)
15. **Jordan, C.T.** (2005) Targeting the most critical cells: Approaching leukemia therapy as a problem in stem cell biology. *Nature Clinical Practice Oncology*, 2(5):224-225. [PMID:16264940](#)
16. **Jordan, C.T.** (2005) The potential of targeting malignant stem cells as a treatment for leukemia. *Future Oncology*, 1(2):1-3. [PMID:16555992](#)
17. **Jordan, C.T.** (2006) Searching for leukemia stem cells – not yet the end of the road? *Cancer Cell*, Invited review, 10:253-254. [PMID:17045202](#)
18. **Jordan, C.T.**, Guzman, M. L., and Noble, M. (2006) Cancer Stem Cells. *New England Journal of Medicine*, 355(12):1253-61. [PMID:16990388](#)
19. **Jordan, C.T.** (2007) The leukemia stem cell. *Best Practice & Research Clinical Haematology*, Invited review, 20(1): 13-18. [PMID:17336250](#)
20. **Jordan, C.T.** (2008) Can we finally target the leukemia stem cell? *Best Practice & Research Clinical Haematology*, Invited review, 21(4):615-20. [PMID:19041600](#)
21. Guzman, M.L, Schuurhuis, G.J., and **Jordan, C.T.** (2009) Leukemia Stem Cells and Therapeutic Targeting. In *Cancer Stem Cells*. Cambridge University Press. [PMID: 28159738](#)

22. **Jordan, C.T.** (2009) Cancer stem cells – controversial or just misunderstood? *Cell Stem Cell*, invited review, 4:203-5. PMID: [19265659](#)
23. Guzman, M.L., and **Jordan, C.T.** (2009) Lessons learned from the study of JunB: new insights for normal and leukemia stem cell biology. *Cancer Cell*, preview article, 15(4):252-4. [PMID:19345324](#)
24. Woodward W.A., Bristow R.G., Clarke M.F., Coppes R.P., Cristofanilli M., Duda D.G., Fike J.R., Hambarzumyan D., Hill R.P., **Jordan C.T.**, Milas L., Pajonk F., Curran W.J., Dicker A.P., and Chen Y. (2009) Radiation therapy oncology group translational research program stem cell symposium: incorporating stem cell hypotheses into clinical trials. *Int J Radiat Oncol Biol Phys*. 2009 Aug 1;74(5):1580-91. [PMID:19540073](#)
25. Cairo MS, **Jordan CT**, Maley CC, Chao C, Melnick A, Armstrong SA, Shlomchik W, Molldrem J, Ferrone S, Mackall C, Zitvogel L, Bishop MR, Giralta SA, June CH. NCI first international workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science. *Biol Blood Marrow Transplant*. 2010 Jun;16(6):709-28. [PMID:20227509](#)
26. **Jordan C.T.** Targeting myeloid leukemia stem cells. *Science Translational Medicine*, 2010 May 12;2(31):31ps21. [PMID:20463365](#)
27. Konopleva M.Y., and **Jordan C.T.** (2011) Leukemia Stem Cells and Microenvironment: Biology and Therapeutic Targeting. *J Clin Oncol*. 2011 Jan 10 [Epub ahead of print]. [PMID:21220598](#)
28. Becker, M.W., and **Jordan, C.T.** (2011) Leukemia stem cells in 2010: Current understanding and future directions. *Blood Rev*. 2011 Jan 7. [Epub ahead of print]. [PMID:21216511](#)
29. Becker, M.W., and **Jordan, C.T.** (2011) Leukemia Stemness Signatures Step Towards the Clinic. *Cell Stem Cell*, Sep 2;9(3):185-6. [PMID:21885015](#)
30. Pei S, and **Jordan CT** (2012) How close are we to targeting the leukemia stem cell? *Best Pract Clin Haematol*. 2012 Dec;25(4):415-8. [PMID:23200537](#)
31. Smith C, Gasparetto M, Humphries K, Pollyea DA, Vasiliou V, **Jordan C.T.** (2012) Aldehyde dehydrogenases in acute myeloid leukemia. *Ann NY Acad Sci*. 2014 Mar;1310(1):58-68. [PMID:24641679](#)
32. Pollyea DA, Gutman JA, Gore L, Smith CA, **Jordan CT.** (2014) Targeting acute myeloid leukemia stem cells: a review and principles for the development of clinical trials. *Haematologica*. 2014 Aug;99(8):1277-84. doi: 10.3324/haematol.2013.085209. [PMID: 25082785](#)
33. Smith C, Gasparetto M, **Jordan C**, Pollyea DA, Vasiliou V. The effects of alcohol and aldehyde dehydrogenases on disorders of hematopoiesis. *Adv Exp Med Biol*. 2015;815:349-59. doi: 10.1007/978-3-319-09614-8\_20. Review. PubMed [PMID: 25427917](#)
34. Pollyea DA, **Jordan CT.** Therapeutic targeting of acute myeloid leukemia stem cells. *Blood*. 2017 Mar 23;129(12):1627-1635. doi: 10.1182/blood-2016-10-696039. Epub 2017 Feb 3. Review. PubMed [PMID: 28159738](#).

35. Pollyea DA, **Jordan CT**. Why are hypomethylating agents or low-dose cytarabine and venetoclax so effective? *Curr Opin Hematol*. 2019 Mar;26(2):71-76. doi: 10.1097/MOH.0000000000000485. PubMed [PMID: 30652974](#).
36. **Jordan CT**. Can we selectively target AML stem cells? *Best Pract Res Clin Haematol*. 2019 Dec;32(4):101100. doi: 10.1016/j.beha.2019.101100. Epub 2019 Oct Review. PubMed PMID: 31779978.
37. Targeting Energy Metabolism in Cancer Stem Cells: Progress and Challenges in Leukemia and Solid Tumors. Jones CL, Inguva A, **Jordan CT**. *Cell Stem Cell*. 2021 Mar 4;28(3):378-393. doi: 10.1016/j.stem.2021.02.013. PMID: 33667359.
38. The Intriguing Clinical Success of BCL-2 Inhibition in Acute Myeloid Leukemia. Pollyea DA, Pei S, Stevens BM, Smith CA, and **Jordan CT**. *Annual Rev of Cancer Biology*. 2021. 5:277-89.